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ABSTRACT
PROTEIN BEHAVIOUR DIRECTED BY HEPARIN CHARGE AND CHAIN
LENGTH

MAY 2014

BURCU BAYKAL MINSKY

Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST

Directed by: Professor Paul L. Dubin

Glycosaminoglycans (GAGs), highly charged biological polyelectrolytes, are of
growing importance as biomaterials and pharmaceutical drugs due to their immense
range of physiological functions. They bind to many proteins; however, the degree of
structural selectivity in GAG-protein interactions is largely unknown .Our studies have
focused on the importance of heparin (a model GAG) charge and chain length in protein
binding in order to explore its potential applications in biofunctional tissue scaffold
materials, as polysaccharide drugs in anticoagulation, and as inhibitory agents in protein
aggregation.

We

used

electrospray

ionization

mass

spectrometry,

capillary

electrophoresis, size exclusion chromatography, dynamic/static light scattering and
electrostatic protein modeling.

vii

Our studies, in the order of presentation in this thesis, showed first that the
electrophoretic mobility of Hp oligomers varies inversely with chain length, which is
explained by reduced counterion condensation at the chain ends or junctions. This
provides an important insight into the biological relevance of sulfation patterns. Second,
charge driven interactions among acidic fibroblast growth factor (FGF), tetralysine (K4)
and heparin decamer (dp10) indicated qualitatively that K4-dp10 complex formation is
consistent with binding being driven by the release of condensed counterions, whereas
FGF-dp10 binding is driven primarily by screened electrostatics. Third, FGF binding to
heparin octamer and decamer chains showed that protein:heparin mixing ratio modulates
multiple protein binding equlibria, and highly sulfated chains facilitate the formation of
multimeric FGF complexes. Next, the effects of heparin chain length on the complexation
between antithrombin (AT) and Factor Xa (FXa) were studied: Shorter heparin oligomer
chains induced binary AT·FXa complexes, while longer chains facilitated AT·FXa·dp20
ternary complexes. We used native heparin chains, which represent an extreme case of
heterogeneity to investigate binding properties with AT. Using a recently developed mass
spectrometry method, limited charge reduction, 1:1, 2:1 and 1:2 (AT:Hp) complexes were
detected. Finally, differences between inhibition and reversal of aggregation by heparin
were observed for AT and BSA aggregations; inhibition may depend on the stage at
which Hp enters the aggregation process, and reversal depends on aggregate size and
morphology.

viii
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CHAPTER 1
BACKGROUND ON HEPARIN AND HEPARIN -PROTEIN INTERACTIONS
1.1 Glycosaminoglycans (GAGs)
GAGs are negatively charged linear polysaccharides found on cell surfaces, in the
extracellular matrix (ECM) and in connective tissue mast cell granules (Figure 1.1). They
bind to a multitude of proteins including growth factor/morphogen families and receptors,
enzymes, enzyme inhibitors, cytokines, chemokines, cell adhesion molecules and various
extracellular matrix components to potentiate cell proliferation, differentiation, adhesion,
wound healing, inflammation, embryonic development, homoeostasis, anticoagulation
and amyloidogenesis.1 The GAG family is classified into four groups depending on the
saccharide structure, glycosidic bond type and the location of sulfates. These groups are:
(1) heparin (Hp)/heparan sulfate (HS), (2) dermatan sulfate (DS)/ chondroitin sulfate
(CS), (3) keratan sulfate (KS) and (4) hyaluronic acid (HA). Their structure consists of
repeating disaccharide units of a hexuronic acid and a hexosamine, either or both can be
decorated with sulfate groups at various positions (excluding hyaluronic acid). GAGs are
covalently linked to highly glycosylated core proteins through serine residues to form
proteoglycans (PGs).2 PGs are highly diverse with respect to type of the core protein, size
and composition of GAG chains. In the GAG family, HS is expressed in almost all cells,3
exhibits structural diversity in a tissue-specific manner,4 and is particularly important in
the modulation of critical cellular functions. Heparan sulfates exert their functions by
protein binding; however, the way in which polydispersity modulates protein binding is
not well understood.
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Figure 1.1: Representation of GAGs in the ECM, on the cell surface and in the mast
cell granules (Adapted from ref. 3).

1.1.1 Heparan Sulfate and Heparin
The versatility of HS, playing the roles noted above for many growth factors,
arises from its structural variability, seemingly random but in fact exquisitely regulated.5,6
After the synthesis of the polysaccharide backbone, the polymer chain undergoes a series
of modifications involving epimerization (transformation of glucosamine unit to Liduronic acid) and the addition of sulfates to various positions by N- and Osulfotransferases (Figure 1.2).

2

Figure 1.2: Repeating disaccharide unit structure of heparin and heparan sulfate

HS is consequently composed of repeating disaccharide units of N-acetylated
(GlcNAc)/N-sulfated glucosamine (GlcNS) and glucuronic acid (GlcA) or iduronic acid
(IdoA).7 The enzymatic modifications do not occur uniformly across the entire chain
during the synthesis; instead, the resultant structure exhibits “domains” of high sulfation,
rich in IdoA and O-sulfation (NS); non-sulfated but N-acetylated (NA) regions; and
alternating NS/NA domains.8 Heparin (Hp) structurally related to HS, but in the mast cell
granules, plays a different role by modulating proteins of the coagulation cascade. Hp
resembles extended NS domains of HS (Figure 1.3) and contains higher degrees of Nand O-sulfation.2

3

Figure 1.3: Schematic representation of the sulfate distribution on the Hp and HS.
Because these domains are more involved in protein binding events, Hp is
commonly used in studies of GAG-protein interactions as a proxy for HS, and their
similarity prompted the use of the term “heparinoid.” In most studies related to GAGprotein interactions, GAG structure is depicted as rigid, and the dynamic nature of these
highly charged polysaccharides in solution have not been given enough attention. 9,10

1.2 Polyelectrolyte properties of GAGs
An essential feature of nearly all polyelectrolytes in solution is flexibility,
stochastic chain dimensions, and characteristic dependences of chain dimensions on MW
and ionic strength. GAGs have exceptionally high linear charge density arising from
extensive post-translational sulfation. Heparin was first recognized as

an anionic

polyelectrolyte almost 35 years ago.11 A variety of physicochemical studies have
demonstrated the polyelectrolyte properties of GAGs. For example, Pavlov et al.
characterized heparin as a semi-flexible, worm-like chain.10 Bertini et al. employed high
performance-size exclusion chromatography (HP-SEC) with triple array detector to
calculate molecular weight and molecular weight distributions of full-length heparin,
heparin fractions and dermatan sulfate. Consistent with the worm-like chain model, they
found intrinsic viscosity [ ] to scale with MW0.84. Different GAG’s exhibited different
4

MW-dependence of [ ] and the radius of gyration.12 Guo et al. showed that accurate
measurement of MW’s of heparin by size exclusion chromatography required salt (1M)
to screen electrostatic interactions of heparin with the column packing.13 These
experimentally supported properties of GAGs coincide with the general polyelectrolyte
behavior, such as displaying various levels of flexibility in solution depending on their
repeat units, having no secondary structure and readily interacting with oppositely
charged surfaces.

1.3 GAG-Protein Interactions

While GAGs have tremendous potential in therapeutic applications and
regenerative medicine, their structure-function relationships are not well understood due
to intra- and inter-chain heterogeneity. This heterogeneity allows them to interact with
numerous proteins to potentiate critical cellular functions (Figure 1.4); however, the
nature and degree of specificity and selectivity in protein binding (a unique set of GAG
sequence arrangements for each protein cognate) is still a matter of debate. The concept
of specificity has been associated with precise GAG sequences that interact with proteins
via pair-wise interactions. In this perspective, the contributions of sulfate groups at
specific locations has been thought to play prominent roles; this model initiated
fingerprinting studies to determine key heparin/HS sequences that are involved in protein
binding.14-18 The attempts to unlock signature structural features of GAGs have been
partially achieved only for antithrombin,18,19 but failed in many cases, especially for
growth factor/morphogen binding.20-22 The high charge density, stochastic sulfate groups
5

distributions , and configuratioal flexibility of GAGs, which could be retained partially at
the bound state could lead a definition of "electrostatic epitopes" , as opposed to well
defined and unique binding motifs. This lack of consensus on the structural requirements
in protein recognition points toward the need for alternative explanations to define the
nature of GAG-protein binding.

Figure 1.4: Suggested roles of Hp and HS

6

1.3.1 Conventional models in protein-Hp binding
In protein-ligand interactions, high-affinity invokes the “lock” and key” analogy
for protein (host) and (small) ligand (guest). However, applying a similar analogy to
protein-GAG systems neglects the inversion of the host-guest relationship. On the other
hand, native GAG chains are replaced by low MW analogs in many studies, with the
characterization of protein-oligoheparin complexes based on crystallography,23-25 docking
or MD simulations.26 The Antithrombin-pentasaccharide model (Figure 1.5) epitomizes
this perspective, positing a distinctive sequence on the Hp chain that interacts specifically
with AT:27 i.e. a specific pentasaccharide is required to activate AT towards coagulation
protease, FXa in the anticoagulation. However, this model failed to take into account the
configurational flexibility of Hp, and the enormous diversity of chemical structures, in
particular sulfation sequences.

Figure 1.5: a) Crystal structure of AT and pentasaccharide; b) suggested hydrogen
bonding (dashed lines) and salt bridges (solid lines) between AT residues and
pentasaccharide charged groups.23
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1.3.2 Alternative models in protein-Hp binding
The pentasaccharide model is increasingly viewed as a “gross approximation”, of
limited applicability for GAG-protein interactions in general.9,28,29 Studies of tightly
bound MW heparin analogs can be misleading, because enthalpic contributions are
overemphasized, while entropic contributions are underestimated.30 Furthermore, recent
Monte Carlo simulations formerly done for a heparin-mimetic binding to BSA,31 which
we now extend to AT (Figure 1.6), point clearly to a dynamic form of binding in which
conformational flexibility of the polyelectrolyte is not lost in the bound state (consistent
with current ideas of “plasticity” and “promiscuity”). 9,32
The dynamic nature of GAGs was also considered by Lander et al. who
emphasized the contribution of GAG in binding kinetics rather than thermodynamics.33
He proposed that GAGs act catalytically on the cell surface to capture growth factors and
growth factors receptors. In blood coagulation, heparin basically increases the rate of
Antithrombin-Thrombin or Antithrombin-Factor Xa interaction. Accordingly, the
interaction can be considered in two steps: encounter and reaction. The first is driven by
the physics of diffusion for the binding on the same heparin chain of AT and the
coagulation protease, with the GAG chain acting as a surface to capture the interacting
partners. Similarly, on cell surfaces, HS proteoglycans increase the rate of growth factor
and receptor encounters by decreasing the dimensionality from 3-D to 2-D.33
Early views of specificity, i.e., the nature of the role of Hp/HS sequence in GF
recognition, have been challenged by recent findings of promiscuity of binding between
highly sulfated GAG chains and growth factors. Empirically, the correlation of GAG
8

sulfate density with GF binding appears to exist somewhat independently of precise
location of sulfate groups. For example, Catlow et al. showed that the interaction of
hepatocyte growth factor/scatter factor (HGF/SF) with HS is dominated by electrostatics
and that HS sulfate density affects the selectivity.34 Krueger et al. found that various
FGFs share the same binding domain on HS, with affinity correlated with the level of
sulfation.21 Jastrebova et al. found correlation between overall O-sulfation levels and the
stability of the FGF-receptor-HS.35 Zhang et al.

showed that the higher degree of

sulfation on heparin chains is preferred in interleukin 7 (IL-7) interactions.36 These
findings point to the need for a new concept of GAG-protein specificity that considers
charge complementarity between the protein and the related polyanion, i.e. “there is an
intermediate specificity based on the gradient of electrostatic interactions that are a
function of relative charge densities, in contrast to high conformationally based structure
specificity.”37 In addition, arrangements of NS and NA blocks have been shown to
provide functional domains for protein binding. 38 For example the interferon-gamma
(IFN ) binding site consists of 24 disaccharide units contains two terminal sulfated
domains, each binding to one IFN monomer,39 and separated by a nonsulfated G1cArich sequence. Similar binding site exists for platelet factor 4 (PF4),40 interleukin-8 (Il8),41 RANTES42 and vascular endothelial growth factor (VEGF).43 Most of these proteins
are either multimeric in solution or multimerized upon binding to HS.
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Figure 1.6: Coarse-grained Monte Carlo simulation showing the mobility of bound
synthetic polyanion resides on the positive domain of AT, but never stops moving (I
=10mM, pH=6.8). Red and blue correspond to the negative and positive potentials,
respectively and they have been calculated using non-linear Poisson- Boltzmann
equation (Courtesy of Daniel Seeman).

1.4 Roles of electrostatics in Hp-Protein binding
Heparin-protein binding affinity arises principally from the electrostatic
interactions common to polyelectrolyte-protein systems,44,45 for which different models
have been widely applied. One model inspired by theories for the salt dependence of
oligolysine-DNA interactions,46,47 has been applied to DNA-protein binding. The linear
dependence of log Kobs (equilibrium association constant) on log I (ionic strength) is
consistent with a purely entropic

Gobs, which arises from the release of DNA

counterions (Figure 1.7). However, directly replacing oligolysines with proteins fails to
consider the influence of protein charge anisotropy.48 Nevertheless, extension of this
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treatment to Hp-protein binding yields a physically realistic value of Hp structural charge
density deduced from measured dlogKobs / dlog I.49

Figure 1.7: The dependence of association equilibrium binding constants Kobs on
the salt concentration for KWK-CO2 (●) and RWR-CO2 (○) interactions with
heparin (from ref. 49)

On the other hand, many polyelectrolyte-protein systems show clearly different
salt dependence more consistent with Debye-Hückel screening.44,50 This last model takes
into account protein charge anisotropy, and effectively accounts for the non-monotonic
salt dependence seen when polyelectrolytes (e.g., heparin) bind to proteins with net
charge of the same (i.e. negative) sign, through a domain of opposite (i.e. positive)
charge, best identified through representation via protein charge calculations.51 Therefore,
it is possible to account for the observed salt dependence of protein-Hp binding by using
specific models of heparin binding along with quantitative protein visualization.28,51 Non11

monotonic ionic strength dependence was observed for AT binding of both full length
and low molecular weight heparin. In this system, maximum binding occurs at 5 < I < 30
mM (Figure 1.8), where the Debye length (κ-1~0.3/√I) is closer to the protein radius
(indication of the combination of short range attractions and long range repulsions).28

Figure 1.8: Non-monotonic salt dependence of AT binding with Hp and low
molecular weight heparin, tinzaparin using frontal analysis continuous capillary
electrophoresis (FACCE), from ref. 28.
1.5 Low Molecular Weight Heparins: Therapeutic Significances
The structural complexity of heparin is the major barrier for therapeutic
applications of heparin. In order to reduce this complexity, efforts have emerged to
generate low molecular weight Hp chains, which are composed of enzymatically or
chemically depolymerized native heparin chains (MW 5,000 to 8,000 Da). The
commercially available low molecular weight heparin analogs exhibited longer plasma
life time than native heparin and have been safely applied in the treatment of
anticoagulation and venous thromboembolism. 52
12

In addition, reduced heterogeneity

facilitates characterization of these Hp analogs and investigation of their protein
interactions using various analytical tools. Accordingly, the small molecule Hp surrogates
improve the “applicability” of certain experimental technique; however, such
oversimplified surrogates of native Hp could deviate from the biologically relevant
counterparts (Figure 1.9). Thus, there should be an adequate balance between
“engineered” selective Hp chains and the biologically relevant Hp chains that could
initiate substantial cellular response.

Figure 1.9: Schematic representation of the chain length and biofunctionality
relationship of Hp

1.6 Aim and Outline of the Thesis
The purpose of this thesis is to elucidate structure-activity relations in
glycosaminoglycan-protein binding. These are not well understood due to the immense
polydispersity of heparin (Hp), the model GAG. The effects of GAG overall sulfation,
saccharide sequence arrangements and chain length are still controversial. To address
these issues, electrospray ionization mass spectrometry, capillary electrophoresis and
dynamic light scattering were applied to systems of Hp and its oligomers in combination
with either Antithrombin (AT) or Fibroblast Growth Factor (FGF). The effects of heparin
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chain length and charge density were investigated in directing protein behavior, i.e.,
inducing complex formation or modulating higher-order protein assemblies.
The physicochemical properties of native heparin and heparin oligomers were
studied using capillary electrophoresis and electrospray mass spectrometry (ESI-MS) as
presented in chapter 2. This study indicates an inverse relationship between chain length
and electrophoretic mobility of heparin oligomers, which can be explained by a recent
theory of polyelectrolyte end effects. Chapter 3 explores mechanistic differences in the
binding of a heparin decamer binding to a growth factor vs. an oligopeptide, with
consideration of potential applications of heparin oligomers in tissue scaffolds. The effect
of heparin oligomer chain length and charge density in FGF-1 binding and the induction
of multimeric complexes of FGF-1 are demonstrated in chapter 4. Chapter 5 explores the
heparin chain length dependence of FXa binding, focusing on the capabilities of various
length Hp oligomers to induce binary and ternary complexes (chapter 5). In addition to
Hp oligomers, AT and native heparin complex formation were studied using a recently
evolved technique, limited charge reduction with FTICR MS, and these results are
presented in chapter 6. Finally, studies that show inhibition and reversal of aggregation of
antithrombin and bovine serum albumin by native heparin are presented in Chapter 7.
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CHAPTER 2
COUNTERION CONDENSATION ON HEPARIN OLIGOMERS
Minsky, B. B.; Atmuri, A.; Kaltashov, I. A.; Dubin, P. L. Counterion Condensation on
Heparin Oligomers. Biomacromolecules 2013, 14, 1113-1121.
2.1 Abstract
The electropherogram of native heparin shows a broad distribution of mobilities µ
which truncates abruptly at a notably high µ = 4.7x10 -4 cm2V-1s-1. This highly skewed
mobility distribution is also found for the 20-saccharide chain which shows from mass
spectrometry a more uniform (symmetrical) with respect to sulfation level. Since a
partially degraded heparin exhibits oligomer peaks with µ> 5x10 -4 cm2V-1 s-1 (appearing
to escape the limitation of the mobility value for native heparin), we examined the
electrophoretic behavior of chain-length monodisperse heparin oligomers.

Their

mobilities varied inversely with the logarithm of the contour length L, for L from 3 to 10
nm and reached an asymptotic limit for L> 20 nm. The generality of this effect was
indicated by similar behavior for oligomers of poly(styrenesulfonate). A recent theory of
polyelectrolyte end effects (Manning, G. S. Macromolecules 2008, 41, 6217-6227.), in
which chain termini exhibit reduced counterion condensation was found to account
quantitatively for these results. A qualitative explanation for the anomalously high value
of µ of native heparin, 10-20% higher than those seen for synthetic polyelectrolytes of
higher linear charge density is suggested on the basis of similar junction effects
(Manning, G. S. Macromolecules 2008, 41, 6217-6227.), which reduce counterion
condensation at the interfaces of regions of high and low sulfation. We suggest that these
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effects should be considered in models for the biofunctionality of the regulated high and
low sulfation (NS/NA) domains of heparan sulfate.

2.2 Introduction
The ability of glycosaminoglycans (GAGs) to biofunctionally bind a multitude of
proteins is related in some way to their immense heterogeneity and variable sulfation
patterns, but this same heterogeneity poses a problem for virtually all methods of
investigation. GAGs are the most highly charged macromolecules in animals, and their
affinity for proteins must involve significant electrostatic forces, including even longrange repulsions from the globally negative charge of most “heparin-binding
proteins”.9,28 Evidence exists that the negative charge arising from GAG sulfation is
modified by counterion condensation, a well-established phenomenon for both natural5357

and synthetic58,59 polyelectrolytes. The biophysical consequences of this are not

understood, even though counterion release is likely to play a role in GAG-protein
binding.49 The issue is further complicated by the immense intrinsic heterogeneity of
GAGs and the corresponding polydispersity of sulfation patterns, a central problem in
efforts to resolve GAG structure-function relations.30,45 Electrophoretic mobility
measurements have provided direct validation of counterion condensation, 58-62 but
electropherograms of native heparin are naturally quite complex.63 Heparin oligomers
provide a level of simplification suitable for electrophoresis in conjunction with
electrospray ionization mass spectrometry (ESI-MS).
The key to structure-function relations for GAGs clearly involves elucidation of
their sulfation patterns;22,64 regulation of sulfation facilitates their roles in angiogenesis,
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cell signaling, proliferation, and blood coagulation. 2,65-67 After elongation, heparin/HS
chains are subjected to enzymatic modifications as opposed to being produced by a direct
genetic template. The final chains exhibit continuous domains of N-sulfation, Nacetylation and N-sulfation (NS/NA-domains), and unmodified N-acetylation (NS,
NA/NS, and NA-domains).7,68 Epimerization and O-sulfation then preferentially occur in
the vicinity of NS domains.

Contrary to HS, heparin does not have “domains” of

sulfation, but instead extended O-sulfated NS domains. In this way, heparin serves as a
good model to examine the way in which high charge density is a central feature in the
affinity for multiple proteins.
Elucidation of heparin-protein energetics has proceeded by analogy to DNAprotein energetics, which rests on measurements of the ionic strength dependence for
DNA-oligolysine interactions47,69 subsequently extended to DNA-protein binding.70 Two
distinct models have generally been invoked to explain the suppression of
polyelectrolyte-protein binding with added salt.

The first evolved from counterion

condensation theory developed by Manning,54,55 and extended by Record69,70 to identify
the release of sodium ions from DNA as a driving force for its binding to oligolysines.
Conceptually replacing DNA with heparin, Lohman and Mascotti49 measured the saltdependent binding constants for heparin with cationic peptides and concluded that a
purely entropic

Gobs arises from the release of heparin counterions. Replacing

oligolysines with proteins, however, raises the possibility of the influence of protein
charge anisotropy entirely absent in the DNA-oligolysine model.48 A distinctly different
salt effect arises from screening characterized by the Debye-Hückel screening length
9,28,51

-1

,

which takes into account the decay of small ion imbalance near the macroion, an
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effect completely distinct from the expulsion of condensed counterions to the bulk
solution in the Manning54,55 and Record69,70 models.
While experiment suggests that heparin may be subject to counterion
condensation, GAGs introduce a level of heterogeneity not encountered with DNA,
olioglysines, or proteins. Counterion condensation theory states that the polyelectrolyte
effective linear charge density is lower than the structural charge density when the
average spacing between charges b is smaller than the Bjerrum length lb (The latter , lb, is
the distance between two unit charges at which the Coulomb free energy is thermal
energy, kBT). When

= lb/b >1, the ionic distribution around the polyelectrolyte is not

stable; therefore monovalent counterions condense to reduce

to 1. Evidence for

counterion condensation on GAGs arises from several facts: NMR shows that calcium
ion binding to heparin does not follow a mass-action law;71 chondroitin sulfate and
keratan sulfate exhibit similar osmotic activities despite the higher sulfation of the
former;72 and the effective charge of heparin from the Donnan distribution is much less
than its structural charge.73 GAG heterogeneity, while recognized, could not be explicitly
treated in these studies. Inter- and intra-chain heterogeneity of these GAGs seriously
complicates application of the original counterion condensation theory, a challenge which
can be greatly simplified with heparin oligomers monodisperse with respect to chain
length.
This reduction of polydispersity makes it possible to take advantage of high
resolution methods: capillary electrophoresis (CE) and mass spectrometry (MS). CE was
used to measure the mobilities of single stranded DNA oligomers of variable charge
density at fixed length, or variable degree of polymerization (dp) and at fixed charge.74
18

For heparin oligomers, the resolving power of CE has been mainly directed towards
characterization of the structural heterogeneity of oligomers.75-79 Since MS of GAGs
provides a description of the distribution of sulfation levels,80-83 it can be complementary
to CE which provides a description of the distribution of mobilities.84,85 Of special
interest here is the relationship between electrophoretic mobility and sulfation level, since
the dependence of mobility on structural charge density has been a central feature in
studies validating counterion condensation.58,63,73,86
Here we measure mobility distributions for “clinical” heparin, low-MW heparin,
and paucidisperse heparin oligomers from hexasaccharide to icosasaccharide (dp6-20),
and compare them to distributions of mass and sulfation levels, and distributions of
effective sizes, obtained by ESI-MS and SEC, respectively. The mobilities for the most
highly sulfated components of the oligomers all show the same inverse length
dependence as seen in oligomers of PSS in 2-25 nm regime,58,84 but contrary to the
behavior of oligomers of single-stranded DNA.74 Our results for the heparin oligomers in
the 2-25 nm length regime is in good agreement with a theory for counterion
condensation subject to end effects.87 The results are directly relevant to thermodynamic
analyses put forward for the binding of heparin oligomers to proteins, and have
implications for the contribution of counterion release to the binding of proteins to
heparin chains with regulated patterns of sulfation.
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2.3 Experimental
2.3.1 Materials
Heparin hexa, octa, deca and icosasaccharides (dp6, dp8, dp10, dp20) generously
donated by Dr John Gallagher from Iduron, were prepared by partial heparin lyase
digestion, followed by high resolution gel filtration. Full-length “native” heparin was
purchased from Sigma. Low molecular weight heparin, tinzaparin, (5000 Da) provided by
LEO Pharma (Ballerup, Denmark), was prepared by enzymatic depolymerization. Native
heparin contains longer heparin chains, with average 50-disaccharide units, and
tinzaparin includes 2 - 24-mer chains.

2.3.2 Methods
2.3.2.1 Capillary Electrophoresis (CE)
Capillary electrophoresis (CZE) of heparin oligomers was performed using an
Agilent instrument equipped with a diode array multiple wavelength detector. The runs
were monitored at 200 and 232 nm. An uncoated fused silica capillary with dimensions
50 µm x 33 cm (24.5 cm effective) was used. The voltage applied across the capillary
was fixed at 12 kV, and the temperature was maintained at 25.0 °C. The injection of the
samples was done in hydrodynamic mode, applying 50 mbar for 3 seconds at the inlet
capillary. New columns were rinsed for one hr with 1 N NaOH, followed by one hr with
Milli-Q-H2O. Between each run, the capillary was reconditioned for 3 min with 0.1 N
NaOH, followed by water and run buffer. The concentrations of heparin oligomers (dp6dp20) were 1 g/L, native Hp was 5 g/L and tinzaparin were 7 g/L. This difference in
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concentration between Hp and Tz has no effect on the results, inasmuch as identical
electropherograms are obtained over the range of 1-5 g/L for either heparin or Tz.
Heparin oligomers were run in triplicate to verify reproducibility. The run buffer was
10mM sodium phosphate at pH 6.8. The electrophoretic mobility was calculated as:
v0

v1
E

L D LT
V

(

1

1

tm

ts

)

Eq. 2.1

where v0 and v1 (cm s-1) are the electroosmotic velocity (EOF) and solute velocity,
respectively; E is the strength of the applied electric field (V cm -1); LD is the effective
length of the capillary, and LT is the total length of the capillary (cm); V is the applied
voltage; and tm and ts are the migration times of the reference marker (mesityl oxide) and
the sample, respectively.

2.3.2.2 Mass Spectrometry (MS)
Stock solutions (2 g/L) of dp6, dp8, dp10 and dp20 in water, were diluted to 10
µM with 10mM NH4 Ac. Mass spectra for dp6-10 were obtained using a QStar-XL hybrid
quadrupole-time-of-flight MS equipped with a nano-ESI-source (AB Sciex, Toronto,
Canada). Sulfate group loss was minimized by applying mild desolvation parameters
(Declustering potential (DP): 40, Focusing Potential (FP): 150, DP2: 15). The
representation of the assigned peaks follows the Roepstorff-Henriksen nomenclature,80
(X,Y,Z), where X = degree of polymerization, Y = number of sulfate groups and Z =
number of acetyl groups. All MS analysis for dp6-10 were carried out in the positive ion
mode; therefore NH3 adduct formation was observed depending on the level of sulfation.
The extent of NH3 adduct formation was determined using the correlation between charge
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state and the number of adducts provided by Abzalimov et al. for heparin hexamer. 88 The
mass measurement of dp20 sample was carried out with a Bruker's SolariX fourier
transform ion cyclotron resonance mass spectrometer (FT-ICR MS) equipped with a 7-T
magnet (Bruker Daltonics, Billerica,MA) using internal calibration at a 100 000 mass
resolution.

2.3.2.3 Size Exclusion Chromatography (SEC)
The hydrodynamic size distribution of native heparin and tinzaparin were
determined on a TOSOH SW2000 size exclusion column equipped with UV detector at
232 nm with an injection volume of 20 μL using 150mM pH 6.9 NH4Ac, as mobile
phase. The SEC column had V0 = 2.3 mL (by DNA injection), and Vt = 5.4 mL (by
acetone injection). The calibration curve (log R h vs Ve) for the TOSOH SW2000 column
was constructed using protein standards of thyroglobin (Rh = 7.9 nm), antithombin (Rh =
3.9 nm), bovine serum albumin (Rh = 3.5 nm), ovalbumin (Rh = 3.0 nm), β-lactoglobulin
(Rh = 2.6 nm), carbonic anhydrase (Rh = 2.3 nm), ribonuclease A (RH= 1.8 nm), and
cytochrome C (Rh = 1.6 nm). The universal log RH vs Ve curve89 was converted to the
heparin calibration curve (log Mw vs Ve) by using an RH-Mw relationship for heparin
based on measurements for various heparin M w fractions10 and diffusion coefficients (DT
= 6πη RH/kBT) in reference 10.

2.4 Results
Several important features appear in Figure 2.1A, which shows superimposed
electropherograms of native heparin and Tinzaparin. (1) The electropherogram of native
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heparin was abruptly truncated at µ = 4.7 x10-4 cm2 V-1 s-1 in a manner uncorrelated with
the shape of the molecular size (SEC) distribution in Figure 2.1B. This result is consistent
with limitations due to diminution of effective charge by counterion condensation for
polyelectrolytes with >1.55 However, the limiting mobility is remarkably high: a search
of the literature58,63,84,90 produces only one report of a mobility91 as high as our result for
µL∞ of heparin. (2) Mobilities of the oligomers (dp ≤ 20) are even larger than the
limiting value for native heparin. The SEC chromatograms show the expected level of
overlap of molecular size distributions in that roughly 1/3 of the mass of heparin is within
the MW range of Tinzaparin. Nevertheless, nearly 70 % of the species in Tz display
larger values of mobility than any native heparin components, i.e. µ> 4.7 x10 -4 cm2 V-1 s1

.

1.
Figure 2.1: Comparison of native heparin (black) and low-MW heparin
(Tinzaparin, Tz) (blue). (A) Electropherograms obtained at 10 mM phosphate
buffer at pH 6.8 (detection at 200nm). (B) Size exclusion chromatograms of native
heparin and tinzaparin on TOSOH SW2000 column in 150 mM Ammonium acetate,
pH 6.9 (detection at 232 nm).
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The appearance of well-resolved species at one end of the distribution of
mobilities, and also at one end of the distribution of sizes prompted us to consider a
hypothetical correlation between small size and high mobility for Tz species (vide infra).
While a similar correlation was noted for olgiomers of PSS 58,84 and acrylic acid,92 no
physicochemical explanation for such common behavior of linear PE oligomers has been
offered. The striking observations are thus (1) the high mobilites for native heparin,
nevertheless abruptly truncated at µ = 4.7 x10-4 cm2 V-1 s-1; and (2) the even higher
mobility of Tz oligomers, as if they were not subject to counterion condensation. We will
show later that different structural features within heparin lead to these two effects.

Figure 2.2: Qualitative comparison of the shapes of distributions from capillary
electrophoresis and mass spectrometry for dp 20. A) The electropherogram of
heparin dp20 (1 g/l) in 10 mM phosphate buffer, pH 6.8. B) Mass spectrum of dp20
obtained at -5 charge states using FT-ICR MS (buffer: 50:50 MeOH: H2O with 10
mM ammonium acetate)

24

The electropherogram and mass spectrum of dp 20 in Figures 2.2A and 2.2B
make it possible to compare mobility and mass distributions. Mass distributions could be
recognized as distributions of sulfation levels: all signals correspond to dp20 chains
having in common the components shown in Figure 2.3 with R1 and R2 groups
designating variations due to post-polymerization enzymatic modification. Mass
spectrum showed the number of SO3H in dp20 ranges from 22 to 29. While the
distribution of mobilities is truncated at µ = 4.9 x10-4 cm2 V-1 s-1 in CE, the distribution of
sulfation is somewhat symmetrical in MS; therefore we can suggest that the most highly
sulfated oligomers (1.5 sulfates per saccharide on average) eluting at the leading edge of
the electropherogram. It was obvious that the truncation of the mobility for dp20 arises
from the same effect demonstrated for heparin in Figure 2.1A.

Figure 2.3: Representation of heparin structure

The behavior of the oligomeric components seen in Figure 2.1A was explored
using size-fractionated oligoheparins that are monodisperse with respect to chain length
(dp). The breadth of the electropherogram for dp 20 in Figure 2.2A is attributable to
sulfation, variable with respect to sequence arrangement and degree (sulfates per
saccharide repeat unit, DS). A leading edge for dp20 in Figure 2.2 at µ = 4.9 x10-4 cm2
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V-1 s-1 is seen as well for dp 6,8 and 10 in Figure 2.4; the mass spectra for these, while
insensitive to sequence arrangement, show that these leading edges can be assigned to the
highest average sulfation level, DS = 1.5. For this reason, we use the leading edge
mobility µmax to establish chain length dependence, i.e. at constant DS = 1.5. Figure 2.4A
shows the dramatic effect of chain length on mobility, as anticipated from Figure 2.1A,
focusing on the DS = 1.5 components. Table 2.1 summarizes molecular weight, contour
length L and µmax for heparin and also incorporates comparable results for oligomers of
sodium poly(styrenesulfonate) (to be discussed below).

Figure 2.4: A) The electropherograms of heparin oligomers (1 g/L) at 10 mM
phosphate buffer, pH 6.8 B) Individual mass spectrum of heparin oligomers (dp6,
dp8, dp10) at +2 charge states (Buffer: 10 mM ammonium acetate, pH 6.8). (X, Y,
Z) represents degrees of polymerization, number of sulfate groups and number of
acetyl groups, respectively.
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Table 2.1: Mobility versus contour length for heparin oligomers and NaPSS
Heparin

NaPSSd
Mw, x10 -3
g/mol
1.6
5.4
12
35.2
70
88
250
500

μ max (40mM)
μ max (10mM)
La (nm) μ max (10mM)
Lc( nm)
5.3±0.3
dp4
2b
5.3b
2.4
4.72
5.1±0.3
dp6
3
5.2
8
4.48
4.7±0.3
dp8
4
5.1
18
4.25
4.26
dp10
5
5.1
52
4.20
4.26
dp20
10
4.9
104
4.28
4.26
native
24
4.7
131
4.22
44
4.26
4.7
372
4.20
65
4.26
4.7
744
4.20
10
a: Disaccharide length 1nm
b: From tinzaparin electrophoregram.
c: NaPSS repeat unit contour length 0.25 nm
d: Data for 4 0mM is taken from reference 85. The data for 10 mM is calculated using
values in reference 58 and 84. Contour lengths calculated as Mw/m0 , where m0 is the
residue mass corrected for degree of sulfonation.
2.5 Discussion
Data from Table 2.1 for dp6-20, presented in Figure 2.5 show that µmax varies
inversely with log L, converging on µL∞ for native heparin (dotted line). The mobility of
dp20 coincides with the electrophoretic front of native heparin (Figure 2.1A), because
counterion condensation in both cases determines the maximum possible mobility. In
order to establish the generality of this effect, we plot in the inset of Figure 2.5 similar
data for oligomers of sodium poly(styrenesulfonate) (PSS), both as the values given in
reference 85 at 40 mM salt, as well as values extrapolated to 10 mM salt using the saltdependences in references 58 and 84. With either data set, PSS mobility decreases with
increasing chain length, reaching µL∞ ~ 25 nm, very close to the behavior for heparin,
although µL∞ shows a significant 10% diminution relative to heparin. Overall, Figure 2.5
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suggests a fundamental relationship between contour length and mobility independent of
structural detail. We note that the monotonic behavior of µL seen in Figure 2.5 does not
persist for PE oligomers below L = 2 nm.58,84 Such small molecules, not subject to
counterion condensation, and with complex frictional properties, should not be viewed as
members of the apparently homologous series of heparin dp6-20 and their behavior is
beyond the scope of the present study.

Figure 2.5: Leading edge mobility µmax versus contour length for heparin oligomers
(dp4-dp20) of DS = 1.5, and limiting value for native heparin (red dotted line). The
open square is used to indicate that the mobility of dp4 was taken from the
tinzaparin electropherogram (Figure 2.1A). Inset: Mobility vs. contour length for
poly(styrenesulfonate) (PSS) measured at 40 mM, from ref 85, and the calculated
mobilities for 10 mM, using the experimental PSS mobility data for various ionic
strengths from refs 58 and 84. Arrows indicate the contour length at which the
limiting mobility is reached.
28

We calculate from structure that the mean dimensionless structural linear charge
densities

for Hp (2.84) and 80 % sulfonated NaPSS, (2.25) are essentially independent

of chain length, so that explanation of the L-dependence of Figure 2.5 must be sought
elsewhere. While relationships between friction coefficient and chain length have been
proposed,93 it is difficult to understand why that effect would truncate at a common
length for different polyelectrolytes. For this reason, we turn to the L- dependence of the
effective value of , i.e. the charge density after counterion condensation.
Explanation of these observations appears in a recent treatment of end effects on
eff

for oligopolyelectrolytes.87 In brief, the electrostatic potential arising from a sequence

of neighboring polyelectrolyte units responsible for counterion condensation must be
diminished at the sequence termini, e.g. at chain ends. The increasing fraction of terminal
sulfate groups with decreasing dp is then responsible for the reduced counterion
condensation. This is equivalent to a monotonic increase in

eff

for shorter chains and

accounts for the remarkably high mobilities noted for dp 4-10 in Figures 2.1A and 2.5.
The equilibrium value of the effective charge fraction f(s) for any segment along
the length of a polyelectrolyte oligomer with univalent counterions is given by;87
f (s)

1

(1

2

ln( b )

Eq. 2.2

ln( s / b )

where κ is the inverse of the Debye screening length, s the distance from the end, b the
axial spacing between neighboring charged groups, and ξ the dimensionless charge
density parameter:
e
4

2

k B Tb

lb

Eq. 2.3

b
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Here, e is the electron charge, ε the permittivity of the solvent, k B the Boltzmann
constant, and lb the Bjerrum length. In order to calculate the effective charge fraction for
heparin oligomers, each disaccharide is assumed to have the same average number of
charges, 4 per disaccharide (three sulfates and one carboxylate, viewed identically
because the carboxylate is fully ionized at pH 6.8).

With a length of 1 nm per

disaccharide, b = 0.25 nm and ξ = 2.84. Figure 2.6 shows the way in which heparin
structure is represented in a form consistent with Eq 2.2

Figure 2.6: Representations of an average heparin structure. Above: molecular
structure of the heparin disaccharide unit. Below: representation adopted for
implementation of Eq.2.2: each disaccharide is represented by four segments with
one charge apiece. Actual disaccharide length is 1 nm, 10 average distance between
charges b (segment length) is 0.25 nm.

These resultant values of f(s) are averaged over the values of s for each oligomer
chain to give the mean effective charge fraction fav in Table 2.2. The effective charge
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fraction was calculated at each charge sites and summed over the entire length of the
oligomer, which gives the total effective charge of the oligomer. This effective charge is
then divided by the total number of charge sites to get average f(s). For small oligomers
(dp8 and below) fav/L decreases rapidly with L because condensation effects propagate
only 0.2κ-1 (~0.5 nm) from the ends. The minimum value for fav (full condensation)
approached asymptotically at high L is 0.3. The lower mobilities of NaPSS relative to Hp
in Figure 2.5 (about 10% less) can now be understood as a consequence of its lower
effective charge density fav/b. These lower effective charge densities arise from its
structural charge density 1/b which is 26% lower than that of Hp. This result, µHp/µPSS ~
1.1 is observed even in the limits at high MW. Interpolating the results of Cottet et al.,84
for the ionic strength dependence of high-MW (88% sulfonated) PSS mobility to I = 10
mM leads to an identical result of µHp∞/µPSS∞ = 4.7/4.2. Most importantly, Table 2.2
clearly shows the dramatic increase in the mean segment effective charge with decreasing
chain length as was seen in Figure 2.5.

Table 2.2: Calculated effective charges and charge fractions of heparin oligomers
and NaPSS at I = 10 mM
NaPSS
Heparin
L(nm)

Total
Qstructural

Total
Qeffective

fav

L (nm)

2
3
4
5
10
24
44

8
12
16
20
40
96
176

6.8
8.7
10.3
11.8
18.7
35.6
58.1

0.85
0.72
0.64
0.59
0.47
0.37
0.33

2.4
8
18
52
104
131
372
744

Total
Qstructural
8
25
57
167
333
419
1190
2381
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Total
Qeffective

fav

7.2
15.4
27.9
66.3
120.4
147.7
383.6
735.8

0.91
0.62
0.49
0.40
0.36
0.35
0.32
0.31

Figure 2.7: Contour length dependence of the leading-edge mobilities for heparin
oligomers (dp4, dp6, dp8, dp10, dp20 and native heparin limiting value) compared
to theoretical average effective charge (dashed line). Positions of the two vertical
axes are arbitrary. Inset: Dependence of mobility on theoretical effective charge per
segment length for Hp (○) and NaPSS (Δ).

Figure 2.7 shows that the contour length dependence of measured mobilities
from Figure 2.5 closely resembles the contour length dependence of fav calculated from
Eq. 2.2 (dashed line). This result reflects the interdependence of µ and fav, which is shown
in the inset, although the arbitrary nature of the two ordinate axes limits the interpretation
of the apparent congruence of experiment and theory. Further evidence for a fundamental
basis for this relationship comes from the nearly congruent data for heparin and PSS, at
least in the region of intermediate chain length. The difference between these two
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polyelectrolytes with respect to limiting mobilities will be discussed below. Regardless of
this difference, µL∞ = 4.7 x10-4 cm2 V-1 s-1 -- for heparin at large L -- is a condensation
barrier: chains in excess of L = 20 nm are subject in principle to full condensation. This
barrier is the basis for the truncated electropherogram of native heparin in Figure 2.1A,
and for the leading edge of the electropherogram for dp20 in Figure 2.2A. With further
decrease in L, components of lower degrees of sulfation escape this barrier, leading to the
more complex electropherograms in Figure 2.4A. The different levels of sulfation for
dp6-10 are relatively few in number: the complexity of those electropherograms largely
reflects different sequence arrangements94 that are not distinguishable in the mass spectra,
see Figure 2.2B.
While the end effect explains the dependence of mobility on L for heparin
oligomers, it is necessary to consider the difference in structural charge densities for
heparin and PSS in order to compare those polyelectrolytes. Data for PSS and heparin are
normalized in the inset of Figure 2.7 by multiplying fav by the mean structural linear
charge density, 1/bav. The congruence of results for heparin and PSS in the inset for
5<L<20 nm strongly suggests that the effective linear charge density fav/b is the main
determinant of mobility in the region of intermediate chain lengths.
The convergence of µ as a function of (fav/b) for heparin and PSS in the inset of
Figure 2.7 does not extend to full-length chains inasmuch as the limiting values for
heparin and PSS at L>25 nm (low fav/b here) are 4.7 and 4.2, respectively. This might
reflect differences between heparin and PSS in the value of the friction coefficient per
segment (F). Inverse dependence on L is seen both for the effective charge per heparin
charge site obtained from Eq 2.2, and for the friction per PSS segment obtained from
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simulations.93,95 However, the variation of the latter in the relevant range of L is small93
compared to the variation of fav. Consequently, µ ~ fav/F should increase with L, opposite
to our results in Figure 2.7. Thus, the lower mobility for PSS vs heparin at L>25 nm
cannot be due to a difference in monomer friction coefficients. These simulations for
PSS also show that the value of Lµ∞ at which the charge per monomer becomes constant
is larger than the value of L at which F becomes constant,93 i.e. the charge effect
propagates further from the chain ends than the friction effect.
The value of µL∞ = 4.7 x10-4 cm2 V-1 s-1 for heparin is not only larger than for
PSS, and even exceeds values (µ< 4.263,90) reported for other polyelectrolytes at this ionic
strength. To explain the anomalously high values for PSS and especially heparin, we
consider a common feature of both polyelectrolytes, their non-uniform linear charge
sequences. Here, PSS was prepared by sulfonation of low MWD polystyrene which
results in charge distribution of sulfonation sequence. Similar to the variety of sulfation
sequences in heparin, this could lead to intrachain sequences of low charge, especially at
large L. Reduction of condensation for a charged segment at a junction with a neutral
sequence87 is a natural extension of the diminution of condensation on chain ends. For
heparan sulfate HS, a near cousin of heparin, such low- and high-sulfation domains (NA
and shorter NS domains) are understood to be somehow related to the remarkable breadth
of growth factors whose activities are modulated by HS.22,38,96-100 NS segments at NA/NS
interfaces are thus subject to reductions in counterion condensation. Such junction effects
are expected to be minimal for PSS oligomers, the likelihood of a charged segment
having an uncharged neighbor being only 20%, and the congruence of PSS with
intermediate length heparin oligomers in the inset of Figure 2.7 suggests that they are not
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significant for heparin either. However, it does seem likely that junction effects could be
responsible for the remarkably high electrophoretic mobility of native heparin compared
to e.g. synthetic polyelectrolytes with higher structural charge densities.59
The application of this model to native heparin is beyond the scope of the present
work, but it is of interest to note that the more biologically functional HS is known to
have sequences of high and low sulfation (NS and NA domains) whose arrangement
appears to be strictly regulated.5,101 While the precise role of NS and NA domains in
growth factor binding is the subject of debate, 2,20,22 it is worth pointing out that the
dimensions of the positive “heparin-binding domain” identified on the typically netnegative heparin-binding proteins is similar to the dimensions of the NS domains of
heparin sulfate.38 These domains comprising 2-8 heavily sulfated saccharides, are
characteristically bracketed by NA domains. 97 Thus, junction effects could preserve the
high effective charge density of NS domains by inhibiting counterion condensation. On
the other hand, it has been proposed that heparin-protein binding is analogous to DNAoligolysine interactions, in the sense of being driven by the entropy of expelled
counterions,49,70 in which case an increase in the effective charge of the protein-binding
domain on HS could amplify the binding constant.

At this point, it can only be

suggested that examination of NA/NS domains take into account to relationship between
sulfation patterns and counterion density.

2.6 Conclusions
The truncated electropherogram for native heparin, highly skewed in comparison
to either distributions of molecular size or degrees of sulfation, is best explained by a
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limiting effective charged density arising from counterion condensation. For a partially
cleaved heparin, some oligomers “escape” this counterion condensation limit, in
agreement with the mobilities µ obtained from well-defined heparin oligomers, which
show inversed dependence of mobility on chain length L. The µ vs L relationship is
remarkably similar for oligomers of both heparin and the partially sulfonated PSS;
heparin however exhibits ~10% larger limiting mobility value (µHp∞/µPSS∞ = 4.7/4.2). A
theoretical treatment for polyelectrolyte end effects shows the reduced counterion
condensation, i.e. larger effective charges (fav) for short chains, accounting for the inverse
relationship between µ and L for both heparin and PSS. In addition to the end segments,
junctions separating regions of different charge densities could lead to diminishing
counterion condensation,87 and this effect could be more pronounced for heparin due to
its higher degree of heterogeneity.
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CHAPTER 3

A HEPARIN DECAMER BRIDGES A GROWTH FACTOR AND AN
OLIGOLYSINE BY DIFFERENT CHARGE-DRIVEN INTERACTIONS
Minsky, B. B.; Nguyen, T. V.; Peyton, S. R.; Kaltashov, I. A.; Dubin, P. L. Heparin
decamer bridges a growth factor and an oligolysine by different charge-driven
interactions. Biomacromolecules 2013, 14, 4091-4098.
3.1 Abstract
Full-length heparin is widely used in tissue engineering applications due its
multiple protein-binding sites that allow it to retain growth factor affinity while
associating with oligopeptide components of the tissue scaffold. However, the extent to
which oligopeptide coupling interferes with cognate protein binding is difficult to predict.
In order to investigate such simultaneous interactions, we examined a well-defined
ternary system comprised of acidic fibroblast growth factor (FGF), tetralysine (K4), with
a heparin decamer (dp10) acting as a non-covalent coupler. Electrospray ionization mass
spectrometry was used to assess binding affinities and complex stoichiometries as a
function of ionic strength for dp10-K4 and FGF-dp10. The ionic strength dependence of
K4-dp10 formation is qualitatively consistent with binding driven by the release of
condensed counterions previously suggested for native heparin with divalent
oliogpeptides (Mascotti, D. P.; Lohman, T. M. Biochemistry 1995, 34, 2908-2915). On
the other hand, FGF binding displays more complex ionic strength dependence, with
higher salt resistance. Remarkably, dp10 that can bind two FGF molecules can only bind
one tetralysine. The limited binding of K4 to dp10 suggests that the tetralysine might not
block growth factor binding, and the 1:1:1 ternary complex is indeed observed. The
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analysis of mass distribution of the bound dp10 chains in FGF·dp10, FGF2·dp10 and
FGF·dp10·K4 complexes indicated that higher degrees of dp10 sulfation promote the
formation of FGF2·dp10 and FGF·dp10·K4. Thus, the selectivity of appropriately chosen
short heparin chains could be used to modulate growth factor sequestration and release in
a way not feasible with heterogeneous native heparin. In support of this, human
hepatocellular carcinoma cells (HEP3Bs) treated with FGF-dp10-K4 were found to
exhibit biological activity similar to cells treated with FGF.

3.2 Introduction
Glycosaminoglycans (GAGs) such as heparin (Hp) are incorporated into tissue
engineering scaffolds with the intention of mimicking their ability in the extracellular
matrix (ECM) to sequester and release numerous growth factors (GFs). 7,33,68,99 Effective
assembly strategies accomplish this through specific and non-specific association of
GAGs with matrix components such as peptides. Model ternary systems can facilitate in
vitro investigation of simultaneous complex formation among glycosaminoglycans,
growth factors and scaffold elements, revealing how non-covalent e.g. electrostatic,
interactions can be utilized. Combination of growth factors with peptide and GAG
components of reduced heterogeneity is currently necessary in order to analyze these
ternary systems with powerful characterization techniques such as electrospray ionization
mass spectrometry (ESI-MS).
GF-binding heparinoids have been coupled to scaffold polymers in order to
achieve modulated release of the protein either with or without heparin. The covalent
attachment of heparin to scaffolds has been pursued through many strategies102-109 which
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may obstruct GF binding sites or introduce toxic cross-linking agents.110 This is avoided
by means of oligopeptide scaffold components that bind heparin non-covalently.108,110-113
The scaffold structure and Hp-oligopeptide affinity determine the release rate of HpGF.110,111 The strength of the heparin-GF bond determines both the rate of GF release and
whether it is released along with bound Hp. It is therefore important to consider whether
differences in the nature of two interactions allow them to be independently modulated
by either ionic strength or heparin microstructure.
The model used here for the binding of oliogpeptides to heparin originates from
the counterion condensation theory of Manning,54,55 initially developed to describe the
binding of oligolysines to DNA.47,70 In the oligolysine-DNA case, the driving force is the
entropy of the release of DNA counterions (Na+) from the condensed layer. This leads to
a particular form of the ionic strength dependence of the binding constant: - log Kobs ~ n
log I, where Kobs is equilibrium association constant, I is ionic strength and n is ligand
charge. Lohman and Mascotti49 applied this concept to oligopeptide/heparin binding
(conceptually replacing DNA with heparin) and measured the salt dependence of the
binding constants. Finding linearity of log Kobs vs. log I for heparin and cationic
oligopeptides, they concluded that the measured

G

obs

was purely entropic. This

observation, along with recent direct measurement of counterion condensation by
heparin,114 provides strong evidence for the release of condensed counterion during the
binding of cationic ligands to heparin. However, further extension of the ManningRecord model in which the oligopeptide has been replaced by a protein17,115,116 has since
been questioned on the basis of fundamental uncertainty regarding the expanded role of
long-range interactions.48
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While non-covalent coupling of growth factors to Hp is recognized as a valuable
approach for the development of bio-functional tissue surrogates, questions arise about
“electrostatic” heparin-oligolysine binding vs “specific” Hp-GF interactions. The former
has been widely accepted as non-specific, but the precise nature of the latter has remained
controversial. Models based on the definition of Hp-GF as a cognate system emphasize
“specific”, i.e. short-range forces comprising hydrophobic and pair-wise interactions (Hbonding and salt bridges).117-120 These are thought to impose on heparin precise structural
and/or conformational requirements for protein recognition. However, there is increasing
evidence that strong binding occurs between globally negative heparin-binding proteins
and polyanions,45 especially when polyanion charge distributions are arranged in a way
that minimizes long-range repulsion while optimizing short range attractions with locally
positive protein domains.31,51,121 This can result in a level of selectivity that does not arise
from short-range interactions such as hydrogen-bonding or “ion-pair” formation.9,45
Supporting this perspective, recent findings indicate that various FGFs share the same
GF-binding sites on HS,16,21 where binding affinity is correlated with the extent of
sulfation.21 Catlow et al. showed that the interaction of hepatocyte growth factor/scatter
factor with HS is dominated by electrostatics inasmuch as sulfate density as opposed to
the presence of particular types of sulfation affects the selectivity. 34 Thus the interactions
considered here could be intrinsically promiscuous20,35 and dominated by columbic
forces. There is also growing evidence that these interactions can be highly
selective.122,123
When Hp-GF interactions are viewed in the context of the vast array of
polyelectrolyte-protein interactions,44 the role of ionic strength is to diminish long-range
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electrostatic interactions between Hp and complementary protein positive “patches,”44 an
effect typically parameterized by the Debye-Hückel screening length

-1 9,28,51,124

.

The

possible role of long-range interactions also leads directly to consideration of long-range
repulsion between Hp and the negatively charged domains of many of its morophogen
cognates,125 an additional issue when the oligocationic “ligand” in the Record-Manning
model is envisioned as part of a protein that may be larger than its heparinoid “host”.
The differences in the effects of both Hp microstructure and ionic strength on the
two types of interactions could make it possible to control the relative strengths of Hp-GF
and Hp-oligopeptide interactions either by using appropriate heparin fractions, or by
adjusting salt concentration. Hp microstructure, difficult to define for the immensely
heterogeneous native heparin, can be better identified using GF-specific oligoheparins.
The length of such oligoheparins must be sufficient to allow for non-covalent binding to
both scaffold oligopeptide units and growth factors. Competition between oligopeptide
and GF for the heparin chains could then be modulated if the two types of binding are
driven by different mechanisms, e.g. counterion release for the former and the screened
electrostatics for the latter. These differences could make it possible to tune the two
interactions so that binding of oligopeptide and GF could take place simultaneously. In
theory, end effects on counterion condensation by heparin oligomers87 suggest that the
central saccharide units, rich in condensed counterions, 114 could provide unique sites for
Record-Manning type oligolysine binding, leaving the distal heparin units available for
screened GF binding, i.e. suppressed at length scales larger than the Debye length,
(nm) ≈ 0.3 I -1/2 in 1:1 electrolyte.
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The model system studied in this work allows for in vitro investigation of
simultaneous complex formation among low MW GAGs, GFs and scaffold peptide
elements. The mechanism of ternary and binary complex formation involving these
species could contribute to molecular level understanding of the assembly of scaffolds
and their ultimate behavior in cell culture. A specific hypothesis to be tested is that the
GF binding sites within a given chain have unique sulfate charge densities. Elucidation of
protein “recognition sites” on heparin has been pursued by crystallography, typically
involving assumptions about certain pair-wise interactions not directly related to sulfate
charge densities.23,126
In this work, ESI-MS is applied to determine the stoichiometry and ionic strength
dependences for a ternary model system comprising FGF-1, a heparin decamer (dp10)
and tetralysine (K4). ESI-MS of native state proteins has recently evolved as a very
important tool to detect their non-covalent complexes, revealing compositional details of
the ligand-protein complexes.88,127,128 Increased sensitivity, low sample requirements and
applicability to transient complexes have improved the importance of native ESI-MS.
We examined the effects of ionic strength on the FGF-1-dp10 and K4-dp10 interactions,
and found the latter but not the former to be analogous to the well-known oligolysineoligonucleotide electrostatic model.48,70 Furthermore, our results indicated that the ability
of the components of dp10 to engage in the ternary complex or bind multiple growth
factors depends on their sulfation levels.
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3.3 Experimental
3.3.1 Materials
Heparin decasaccharide (dp10), prepared by high-resolution gel filtration of
partial heparin lyase digestion of high quality heparin, was generously donated by Prof.
John Gallagher from Iduron (Manchester, UK). Acidic fibroblast growth factor (includes
His to Gly 93 mutation to increase stability,129 pI = 7.8) was provided by Prof. Robert
Linhardt (RPI, Troy, NY). Tetralysine (K4) was purchased from Sigma.

3.3.2 Methods.
3.3.2.1 Mass Spectrometry
All experiments were performed with a QStar-XL hybrid quadrupole-time-offlight MS equipped with a nano-ESI-source (AB Sciex, Toronto, Canada). The
measurements were performed using closed (2 μm id) glass nanospray capillaries (New
Objective, Woburn, MA). FGF-dp10 binding experiments were acquired using following
settings of ion optics in the ESI interface: DP: 100, FP: 265, DP2: 15. K4 and dp10
binding experiments were performed utilizing mild ion desolvation conditions (DP: 40,
FP: 150, DP2: 15). FGF-1 was buffer exchanged using Amicon (10kDa cut off) with 100
mM NH4CH3CO2, and the protein concentration was verified by UV-VIS using molar
absorptivity of 17545 M -1 cm -1. FGF, dp10 and K4 were diluted from the stock solutions
to the final concentrations (2 μM, 3 μM and 10 μM, respectively) in the desired
ammonium acetate concentrations. ESI-MS was used to determine stoichiometries of
FGF-1-dp10 complexes, and m/z values of the protein and the complexes were assigned
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with BioAnalyst v1.1.5 (MDS Sciex/Applied Biosystems, Toronto, Canada). The mass
distribution of the protein-bound heparinoid molecules were calculated using the
following formula:
m
z

z

mH

nM

FGF

Eq.3.1

where n represents total number bound FGF-1 molecules, m is the total protons attached
and MFGF is the mass of a single FGF molecule. Since all analyses were performed in the
positive ion mode, it is expected that each ionic species will also contain 4-5 cations
(NH4+). Shaded boxes are used in Figure 3.3 and 3.5 to indicate the mass ranges for
heparinoid species with different extent of sulfation (the overlap is due to the uncertainty
in the number of cationizing agents attached to each polyanionic chain).

3.3.2.2 Computational
DelPhi V. 4r1.1,130,131 which applies non-linear Poisson-Boltzmann equation to
generate the potential surface of the protein, was used to model the electrostatic potential
around FGF-1 (PDB id: 1K5U) and heparin decamer (Solution NMR: 1HPN). The
structures were taken from the protein data bank (http://www.rcsb.org/). The charges of
amino acids on the protein were determined using the spherical-smeared charged model
put forward by Tanford.132

3.3.2.3 Cell Culture and Proliferation Assays
All cell culture supplies were purchased from Life Technologies, Carlsbad, CA,
unless otherwise noted. Human hepatocellular carcinoma cells (HEP3Bs, American Type
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Culture Collection, Manassas, VA) were cultured in modified Eagle's medium (MEM)
supplemented with 10% Fetal Bovine Serum (FBS) and 1% penicillin-streptomycin (P/S)
at 37 oC and 5% CO2. To quantify cell growth in response to growth factors and growth
factor complexes, HEP3Bs were seeded at 10,000 cells/well in 96-well plates (Corning,
Tewksbury, MA), in standard growth medium. After 24h, the medium was replaced with
the serum-free medium containing 1% P/S and either fibroblast growth factor (FGF) or
FGF.dp10.K4, ranging from 0 to 50 ng/mL. We used the CellTiter 96 AQueous One
Solution Cell Proliferation Assay (Promega, Madison, WI) to measure cell proliferation
at 24 h and 72 h. After 3 h of incubation, the absorbance was read at 490 nm with a
BioTek ELx800 microplate reader (BioTek, Winooski, VT).

3.3.2.4 Statistical Analysis
One-way ANOVAs were performed with using Prism v5.04 (GraphPad Software,
La Jolla, CA), the Tukey post-test was used to determine significance of pairwise
differences. Data are reported as mean ± standard error with N = 3. P ≤ 0.05 is denoted
with *, ≤ 0.01 with **, and ≤ 0.001 with **
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3.4 Results and discussion
3.4.1 K4 binding to dp 10

Figure 3.1: (a) ESI mass spectra of dp10 (3 µM) and K 4 (10 µM) in pH 6.8
ammonium acetate at varying ionic strengths. Not shown: free K 4 (m/z = 531, z =
+1). (b) ESI mass spectra of FGF-1 (2 μM) and dp10 (3 μM) in 100, 250, 400, 550
and 1000 mM ammonium acetate. The shaded columns represent (a) dp10 and
dp10·K4; (b) FGF, FGF·dp10 and FGF2·dp10.
Figure 3.1 shows the effect of ionic strength on the binding of dp10 at pH 6.8 to
K4 (a) and to FGF (b). Even though K4 is in molar excess (10:3 K4:dp10), K4 forms only a
1:1 complex with dp10. This is in contrast to the ability of dp10 to bind at least two FGF
molecules. Furthermore, the contour length of dp10 (5 nm) is significantly larger than
that of K4 (~ 2 nm). It appears that the binding energy for the second K4 is diminished,
i.e. binding is apparently anticooperative. Arguments based on variations in local
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sulfation would not explain why there are no dp10 chains that bind two oligolysines. We
therefore explore the earlier studies of oligolysines and heparin, which supported the
model put forward by Manning and Record.46 As noted above, these studies showed that
the driving force for oligocation binding to polyanion (e.g. DNA) is the entropy of the
release of the polyanion’s counterions from its condensed layer. A more recent
theoretical result by Manning for oligo-polyelectrolytes

is the diminution of

condensation at and near chain ends,87 subsequently verified by Minsky et al. for heparin
oligomers.114 Representation of the heparin disaccharide structure (Figure 2.6, above)
neglecting positional variations of sulfation leads to visualization of the chain as treated
in the condensation model (Figure 2.6, below), with the condensed counterion layer
depleted at chain ends. If those ions are involved in the oligolysine binding process, the
strongest K4 binding site would comprise chain units far from the ends of dp10, i.e.
saccharides 3-8 (contour length ~3 nm). The remaining distal regions are incompetent
binders with respect to both length (1 nm) and condensed counterions. To further
examine the applicability of this model, we examine whether the strong binding
suppression with an increase from 40 to 150 mM ionic strength in Figure 3.1(a) is
consistent with the condensed counterion model.
In order to compare dp10-K4 results to those in the highly influential Mascotti and
Lohmann paper,47,49 it was necessary to extrapolate from the binding constants, Kobs,
which were obtained in refs. 30 and 32 for native heparin with a +2 oligolysine (n =2).
While their study49 only covered a narrow range 12 < I < 30 mM, they obtained Kobs ~ I -2
in agreement with theory in which the number of released counterions is equal to the
ligand charge ( - (dlogKobs / dlogI ) = n ),46 subsequently supported by Manning et al.48
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With n = 4, Kobs is expected to exhibit I

-4

dependence for K4. Thus, the dramatic

suppression of binding seen in Figure 1(a) for the ca. 4-fold increase in I from 40 to 150
mM is entirely consistent with the 200-fold ((ca. 40/150)-4) decrease in Kobs as predicted
by theory, suggesting that the binding of K4 to dp10 is driven by the release of condensed
counterions. The remarkably different I dependence in Figure 3.1(b) shows that a
different mechanism must drive the binding of FGF to dp10 at 400 mM; binding based on
the displacement of condensed counterions is not possible when the bulk ionic strength
exceeds 380 mM, the local concentration of condensed counterions for heparin. 48

3.4.2 FGF binding to dp10
In order to compare binding strengths for FGF-dp10 vs K4-dp10, the former was
also investigated using salt concentration as a surrogate for binding affinity. Figure 3.1
(b) shows the formation, in pH 6.8 ammonium acetate, of 1:1 and 2:1 complexes of FGFdp10 at I = 100, 250, 400 mM. If we use the salt resistance of complex formation as a
measure of binding affinity, we find that the FGF-dp10 1:1 complex is more stable than
the K4-dp10 complex (see Figure 3.1), and also the FGF-dp10 2:1 complex. However,
even the FGF-dp10 1:1 complex is fully suppressed at I > 550mM, indicating the role of
screened electrostatics. Although the pH used is only moderately lower that the pI, the
charge distribution is anisotropic leading to a discernible positive domain (Figure 3.2).
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Figure 3.2: FGF-1 (PDB id: 1K5U) electrostatic images for pH 7.0 and I = 400 mM,
550 mM and 1000 mM. 5 Å surfaces (magnitude of charge shown by color intensity,
blue positive, red negative), and equipotential surfaces (grids) +0.2 kT/e and -0.2
kT/e. The heparin decamer (Solution NMR id: 1HPN) is drawn to scale to help
visualize its ability to reside within the FGF positive domain (sulfate groups are
shown in yellow). The pH differences between Figure 3.1 (b) and the DelPhi
calculations have no significant effect on the aminoacid charges
Calculations of screened electrostatics by DelPhi have been recognized as a
quantitative tool for elucidating the electrostatic binding energy of

both protein-

polyelectrolyte50 and protein-protein interactions,133 and comparisons with experimental
results are facilitated by the display of electrostatic potential contours. The potential
contours represented as grids in the DelPhi images arise from the conjoint sum of all
possible pair-wise coulomb forces that are subjected to the moderating influence of the
ionic strength. This screening results from the asymmetric distribution of small ions as
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parameterized by the Debye screening length (

-1

~ I

-1/2

) , the distance at which the

electrical potential due to the protein surface charges decays to 1/e of the protein’s
surface potential.

This approach, which needs to be clearly differentiated from the

behavior of condensed counterions, explains the maximum in binding when

-1

≈ protein

radius seen for binding at pH > pI for polyanions, 51 including heparin.28
This approach here is embodied in the DelPhi images of Figure 3.2 for FGF at pH
7.0 and 400-1000 mM salt. The protein itself is represented at 5Å from Van der Waals
surface to account for retention of heparin and FGF solvation, and the potential contour
grids are presented at ψ = 0.2 kT/e. As shown in Figure 3.2 for I = 400 mM, the volume
between the 5Å surface and the contour grid is sufficient to accommodate at least -5
heparin charges (1.5-2 disaccharide units, ~2-3 nm dp10 segments), a dimension
consistent with the FGF-binding site size on heparin.134 The consequent electrostatic
binding energy then is on the order of 1 kT, which represents the onset of the binding.
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The diminution of this volume seen with increasing salt portrays screening; therefore the
number of dp10 charges bound is reduced at 550 mM and abolished at 1000 mM as seen
in Figure 3.1(b). The predominant role of screened electrostatics does not necessarily
negate release of some bound counterions, but the number of these is debatable. 48
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Figure 3.3: Mass distribution of protein-bound dp10 molecules in FGF·dp10 (blue
trace) and FGF2.dp10 (green trace) determined at ionic strengths of 250 and 400
mM.

The stability of the ternary complex requires not only that K4 not compete with
FGF, but also that the stronger binding of FGF to dp10 does not lead to its occupying all
potential K4-binding sites. As noted in Figure 3.1, dp10 can bind either one or two FGF
molecules; the ratio of FGF2·dp10 to FGF·dp10 decreases with salt concentration I, most
notably near I = 400 mM. This corresponds to a Debye length (κ

-1

= 0.4 nm) suggesting

that screening repulsions at that length scale could weaken the binding.

To further

explore the difference between the first and second binding events, we consider the
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sulfation of dp10 molecule found in FGF2·dp10 vs. those found in FGF·dp10. Figure 3.3
shows, in the absence of K4, the mass spectra of FGF-dp10 complexes plotted on the
adjusted mass scale where the mass of the protein component was subtracted from 2:1
and 1:1 complexes at 250 and 400 mM, and represents in blue and green the collection of
dp10 molecules found respectively in FGF.dp10 and in FGF2·dp10. Given the presence of
free FGF at all conditions, it might appear if one were to neglect the different sulfation
patterns that the binding of FGF is anticooperative at high salt. A more reasonable
explanation can be sought in differences in dp10 sulfation for the first and second binding
sites, presumably higher for the high-affinity first site. The phase transition-like behavior
of polyelectrolytes adsorption on oppositely charged surfaces can be extended to binding
to oppositely charged colloids135,136 and oppositely charged proteins.137 Critical
conditions for binding are then expressed by Eq. 3.2:
c

~

b

Eq.3.2

where σc is the effective charge density of the protein positive patch, ξ is the
polyelectrolyte structural linear charge density, b is an empirical scaling parameter and κ
(nm) ≈ 0.3 I

-1/2

. According to eq 3.2, the critical ionic strength (above which no binding

occurs) is described by κc ~ ξ1/b. If the high-affinity first binding site is more highly
sulfated, i.e. ξI> ξII, then κcI > κcII so binding at site I may persist when binding to site II
is suppressed. Focusing on the results for the 1:1 complexes alone (blue trace in Figure
3), the increase in dp10 sulfation with ionic strength is consistent with eq 3.2. Typical
values of b range from 0.5 to 3, a much smaller ionic strength dependence than the I

-4

dependence of condensed counterion release, as noted in the comparison of Figures 3.1(a)
and (b).
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3.4.3 Ternary complex formation

Figure 3.4: ESI mass spectra of mixtures of FGF (2 μM), dp10 (3 μM), K 4 (10 μM)
in 20 mM pH 6.8 (a) and 100 mM pH 5.5 (b). FGF present as: FGF·dp10·K4;
FGF·dp10; FGF2·dp10; and free FGF.

Figures 3.4 (a) and (b) show the ESI mass spectra for a ternary mixture of FGF,
dp10 and K4 of 2:3:10(µM) stoichiometry at 20 and 100 mM ionic strengths,
respectively. The signal from dp10.K4 is not shown in Figure 3.4(a) due to excess noise,
but K4 does appear in the 1:1:1 FGF·dp10·K4 (ternary) complex. The 5:1 excess of K4
does not impede FGF binding, either because K4 occupies an oligoheparin site distinct
from that of FGF, or because dp10-K4 binding is intrinsically weaker. The ternary
complex is less abundant at 100 mM (Figure 3.4(b)) most likely because high salt
weakens the dp10-K4 interaction (vide supra).
FGF·dp10 and FGF2·dp10 are observed, the former is more abundant than the
latter. The restriction of K4 binding to 1 per chain, despite its small size, can be explained
on the basis of the release of condensed counterions (vide supra), which are more
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abundant in the middle of dp10. On the contrary, if FGF binding were governed by
screened electrostatics, the larger effective charge due to less counterion condensation at
these terminal saccharides could account for facile binding of 2 FGF molecules per chain.

Figure 3.5: The assignment of sulfation levels of dp10 for the FGF·dp10·K4,
FGF·dp10 and FGF2·dp10 complexes presented in Figure 4 (b). (a) Expansion of the
m/z regions of FGF·dp10.K4 and FGF·dp10 complexes (nomenclature by Roepstorff
and Henriksen138 for bound dp10). NH4+ adducts on the unbound FGF are shown
with asterisks (*). The m/z region of FGF·dp10·K4 is amplified 3 times for clarity. b)
Mass distribution of bound dp10 in FGF·dp10 (blue trace) FGF·dp10·K 4 (pink
trace) and FGF2·dp10 (green trace).
Expansion of the spectral region that comprises FGF·dp10 and ternary complex
shown in Figure 3.4 reveal the levels of sulfation of the bound dp10 chains (Figure 3.5 (a)
and (b)). The sulfation density in the ternary complex, slightly higher than that seen in
FGF·dp10, suggesting that dp10 chains with low sulfation (< S12) only bind to a single
FGF, while those with higher sulfation (> S12) can bind K4 along with FGF. The strong
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suppression of K4 binding at high salt noted above is responsible for the observation of an
increase in FGF·dp10 at the expense of the FGF·dp10·K4 ternary complex at high salt.
The extended spectral range at 100 mM salt to include FGF2·dp10 is shown in
Figure 3.5 (b). Here, the masses of FGF, K4 and 2FGF are subtracted from the calculated
mass distribution of the complexes in order to compare the sulfation levels of the relevant
host dp10 chains. Within the limitations of ESI-MS resolution, i.e., the overlapping
distributions due to the uncertainty in the number of cationizing agents attached to each
polyanionic chain, the higher mean levels of sulfation (S14 and S15) of dp10 within
FGF2·dp10 compared to those within FGF·dp10 complexes (S10-14) were observed, and
chains that contain S12-15 appear to bind both FGF and K4. While chains of low
sulfation may bind only one FGF, highly sulfated FGF·dp10 chains appear to be subject
to competition between K4 and FGF for the second binding site. Comparison of the
highly sulfated (15S) dp10 species in Figure 3.5 (b) suggests that FGF preferentially
occupies this site. Since K4 binding depends on the condensed layer of counterions, the
opposing effects of sulfation density and end effects may explain the absence of a clear
effect of the former.
Binding to dp10 by K4 and FGF differ in several ways. The salt dependence of
K4·dp10 complexation is consistent with binding driven by the release of condensed
counterions; on the other hand, FGF binding to dp10 exhibits higher salt resistance and
more complex ionic strength dependence consistent with screened electrostatics. While
FGF2·dp10 complexes are formed over a wide range of ionic strength, dp10 can only bind
one K4. Estimates of the size of the FGF-binding site on heparin suggest ca. two
disaccharides, similar to the mean protein hydrodynamic radius i.e. 2 nm, consistent with
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the maximum number of proteins that can bind to native Hp. 134 K4 (≈ 2 nm contour
length) can then be easily accommodated near the center of dp10 with a distal region of
higher effective charge density accessible for FGF. FGF binding is facilitated by high
dp10 sulfation, whereas the effect of sulfation levels on K4 binding can be obscured by
the conjoint influence of end effects on the concentration of dp10 condensed counterions.
These observations pointed out that control of I and overall sulfation levels of
heprarinoids could be used to manipulate the balance between matrix component- and
growth factor affinity in tissue engineering. The selection of the conditions could be used
to influence the rates of morphogen release and also the presence or absence of heparin
accompanying the free growth factor.

Figure 3.6: Models of FGF release
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The stability of the FGF·dp10 versus K4·dp10 complexes at selected conditions
will determine which bond will break first in the tissue scaffolds to release FGF, and as a
result of this breakage, FGF will be released with or without heparinoid. The use of low
ionic strength (< 40mM) during the assembly process should enhance ternary complex
formation and higher ionic strength of the environment could lead to the dissociation of
the dp10- K4 bond first; then GF would be released in the heparinoid-bound form during
the dissociation process (Figure 3.6). In addition to addition of salt, increasing the
degrees of sulfation definitely promotes capturing a large number of growth factors and
the formation of ternary complexes. Therefore, heparin chains with higher degrees of
sulfation could be used to deliver high concentration of GFs in the tissue environments.

3.4.4 Biological activity of FGF vs FGF·dp10·K 4
We investigated whether the complexation of FGF to dp10 and K4 would alter its
bioactivity when compared to FGF alone (Figure 3.7). HEP3Bs were stimulated with
FGF or FGF complex across concentrations ranging from 0 to 50 ng/mL. We found that
binding of dp10 and K4 to FGF does not significantly alter its activity at any of the tested
concentrations. As expected, HEP3B proliferation at 24h increased by approximately
10% with FGF and FGF complex as compared with the control. After 72 h, cell
proliferation is maximized, and neither treatment showed any significant difference in
proliferation across the concentrations tested here.
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Figure 3.7: FGF·dp10·K4 mixture retains biological activity of FGF·HEP3Bs were
treated with either FGF (black) or FGF·dp10·K 4 (red), and cell proliferation was
quantified at 24 (solid) and 72 hours (dashed). No statistical differences were noted
when comparing cell proliferation with FGF and the FGF·dp10·K 4, at any time
point. Proliferation increases with FGF concentration at 24 hours, and is
maximized at all concentrations at 72 hours. In both formats, FGF of 50 ng/mL is
statistically higher than the no growth factor condition at 24 hours.
3.5 Conclusions
A heparin decamer (dp10) in the presence of tetralysine (K4) can bind either one
or two molecules of acidic fibroblast growth factor (FGF), or FGF and K4, but cannot
bind two molecules of K4. Using electrospray mass spectrometry (ESI-MS) to investigate
the ionic strength effect on the formation of these complexes, we concluded that the
formation of K4-dp10 is driven by the release of condensed counterions. We have
previously shown that the concentration of condensed counterions on dp10 is strongly
reduced near its chain termini, and therefore propose that K4 binding is constrained to the
central region of dp10. The markedly different ionic strength dependence of FGF binding
suggests a different mechanism (based on screened electrostatics), which removes this
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constraint, so that the growth factor can bind along with K4 (“ternary complex”) or along
with a second FGF. ESI-MS characterization of bound dp10 chains in various complexes
indicates that FGF binding is enhanced by heparin sulfation, while K4 binding is
relatively indifferent to it due to competing effects. Cell culture studies indicated that
complexation of FGF in the form FGF-dp10-K4 does not significantly change its
biological activity. These observations suggest the application of shorter heparin chains
as a route to growth factor sequestration and release in tissues matrices could be more
effective than the use of heterogeneous native heparin chains.
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CHAPTER 4
STRUCTURAL DETERMINANTS OF ELECTROSTATIC INTERACTIONS
BETWEEN PROTEINS AND POLYANIONS: AN ESI-MS STUDY OF
FIBROBLAST GROWTH FACTOR BINDING TO HEPARIN OLIGOMERS

Minsky, B. B.; Dubin, P. L.; Kaltashov, I. A.

4.1 Abstract
The interactions between fibroblast growth factors (FGFs) and their receptors
(FGFRs) are facilitated by heparan sulfate (HS) and heparin (Hp). The molecular basis of
this modulation is highly complex due to the structural heterogeneity of HS/Hp, with
regard to both chain length and sulfation. In this work, we employed electrospray
ionization mass spectrometry (ESI-MS) to investigate the association of acidic fibroblast
growth factor (FGF-1) with relatively homogeneous heparins octamer (dp8) and decamer
(dp10). FGF-1 forms 1:1, 2:1 and 3:1 (FGF:heparinoid) complexes with dp8/dp10, and
the fraction of bound protein is highly dependent on FGF:heparinoid bulk stoichiometry.
The multimeric complexes were preferentially formed on the highly sulfated Hp
oligomers. When solution stoichiometry led to only 1:1 complex, the sulfate distribution
of FGF-bound oligomers was skewed from low to high in the complex. These results
showed how interactions between FGF-1 and Hp oligomers are influenced by the heparin
oligomer charge density and bulk mixing ratio, and also demonstrate the power of ESIMS as a tool to study multiple binding equilibria between proteins and highly complex
polyanions.
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4.2 Introduction
Glyscosaminoglycans (GAGs), such as heparan sulfate (HS) and heparin (Hp), are
engaged in a wide spectrum of physiological effects including embryogenesis, immune
response, cell proliferation, differentiation and angiogenesis. All of these are related to
the ability of GAGs to potentiate the activity of numerous signaling proteins,
accomplished largely by mediating the interactions of these growth factors and their cell
surface receptors. The main challenge in characterizing GAG-protein binding arises from
the immensely polydisperse GAG structure due to apparently stochastic post-translational
sulfation patterns. While this polydispersity correlates with promiscuity in protein
binding, the details of the relationship between the sulfation and protein affinity remain
elusive. The fact that GAGs are the most highly charged macromolecules in animals
suggests that electrostatic forces play significant roles in their protein affinity, but such
long-range interactions are typically relegated to supportive roles in protein recognition.
The development of structure-property relations, which would remove a major barrier to
the development of potential biomedical applications of GAG’s, is thus coupled to the
need to understand how sulfation patterns determine binding of their physiological
partners. While many approaches focus on the presence or absence of a particular
glycoside or glycoside substituent, electrospray ionization mass spectrometry (ESI-MS),
focusing on the characterization of individual molecules, can provide unique insights into
the structural distinctions between high and low affinity GAG molecules.
Efforts to characterize HS/Hp interactions with growth factors (GF) have until
recently focused on the contribution of certain sulfation features, such as 6-O- sulfation
for FGF-10, 2-O sulfation for FGF-2, or both for FGF-4 and FGF-7.117,118 The underlying
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assumption is that the protein-heparinoid interaction is driven by pair-matching of basic
residues on the protein and sulfates on heparin, the fact that heparin was clearly and
credibly identified 30 years ago as a polyelectrolyte11 notwithstanding. In most studies,
the importance of more global “charge complementarities” between the protein and the
polyelectrolyte-like heparinoid had been ignored,17,44 thus failing to consider the
heterogeneity and highly dynamic nature of the Hp/HS chains,10 and the well-defined
positive domains of the many globally negative heparin-binding proteins.139 There is
increasing evidence that strong binding occurs between globally negative proteins (such
as antithrombin) and polyanions (such as heparin) when polyanion charge distributions
are arranged in a way that minimizes long-range repulsion while optimizing short range
attractions with locally positive protein domains. This can result in a level of selectivity
that does not arise from short-range interactions such as hydrogen-bonding or “ion-pair”
formation.31,51,121 Supporting this perspective, several groups suggested that GAG-GF
interactions might be intrinsically non-specific. Catlow et al. showed that the interaction
of hepatocyte growth factor/scatter factor with HS is dominated by electrostatics.34
Krueger et al. indicated that various FGFs share the same binding domain on HS, where
binding affinity is correlated with the extent of sulfation.21 Jastrebova et al. extended
these studies to FGF-2 and its receptors, and revealed that ternary complex formation was
related to overall chain sulfation. 20,35 These studies strongly suggest that non-specific
electrostatic interactions can play a role in recognition. 45
For various signaling proteins, certain sequences in GAG structure may either
interact with protein multimers or promote multimerization. 38 In this way, FGF-HS
binding in the distal region of cell surfaces generates FGF dimers along HS
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chains.134,140,141 Evidence, both in vivo and vitro, suggests that these dimers are the
biologically preferred architecture for inducing receptor activation.142 The crystal
structure of FGF-2 with a heparin decamer (dp10) revealed the existence of a homodimer,
or “cis-dimer"143, in contrast to the “trans-dimer” formed for FGF-1 with a 4-5
monosaccharide sequence sandwiched between the two proteins.144 Other oligoheparins
larger than heptasaccharides can lead to biologically active FGF-1 dimers145. In vitro light
scattering studies of full-length Hp have shown that it accommodate 14-15 FGF-1
molecules.134
Sulfation sequence arrangements are clearly determinants of the intrapolysaccharide organization of bound proteins, but the techniques mentioned above only
reflect the average behavior of intrinsically heterogeneous heparin oligomers. On the
other hand, the unmatched resolution of mass spectrometry provides insight into the
behavior of single molecules, clearly correlating sulfation level and protein-oligoheparin
stoichiometry. Native electrospray ionization mass spectrometry (ESI-MS) is thus an
important tool in the detection of non-covalent protein-ligand complexes,146 revealing
compositional details of macromolecular complexes that involve nucleic acid and
heaprin.88,127,128 Increased sensitivity, low sample requirements and ability to detect
dynamic and transient complexes have contributed to the importance in this field.
Therefore, we applied native ESI-MS to probe interactions of FGF-1 and short
heparinoids, focusing on the influences of heparin chain length, extent of sulfation and
solution concentration on the induction of multimeric complexes of FGF-1. Analysis of
the number of sulfate groups on the Hp chains involved in complex formation revealed
the basis of FGF-1 selectivity of Hp chains.
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4.3 Experimental
4.3.1 Materials
Acidic fibroblast growth factor (includes His to Gly 93 mutation to increase
stability,129 pI = 7.8) was provided by Prof. Robert Linhardt (RPI, Troy, NY). Octa and
decasaccharides (dp8 and dp10), prepared by partial heparin lysis, followed by highresolution gel filtration, were generously donated by Dr. John Gallagher from Iduron
(Manchester, UK).

4.3.2 Methods
4.3.2.1 Electrospray Ionization Mass Spectrometry (ESI-MS)
All experiments were performed with a QStar-XL hybrid quadrupole-time-of-flight MS
with a nano-ESI-source (AB Sciex, Toronto, Canada). The measurements were
performed using both closed and pre-opened (1-2 μm id) glass nanospray capillaries
(New Objective, Woburn, MA). ESI-MS was used to determine stoichiometries of FGF1-dp8/dp10 complexes and monitor depletion of dp8/dp10. Growth Factor concentration
was kept constant during each experiment (0.08 g/L, ca. 5 μM) and dp8/dp10
concentration was adjusted to 1, 2.5, 5, 10 and 25 μM at 100 mM NH4CH3CO2 at pH 6.8.
FGF-1 was buffer exchanged using Amicon (10 kDa cut off) with 100 mM NH4CH3CO2,
and the concentration was verified by UV-VIS using molar absorptivity of 17545 M-1cm1

. Dp8 and dp10 were diluted from 2 mg/mL stock solutions. Binding experiments were

acquired using following settings of ion optics in the ESI interface: DP, 100; FP, 265;
DP2, 15 and dp8/dp10 depletion experiments are acquired under mild ionization
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conditions (DP, 40; FP, 150; DP2, 15),where DP is the declustering potential and FP is
focusing potential. The mass distribution of the protein-bound heparinoid molecules were
calculated using the Eq. 4.1.
m
z

z

mH

nM

FGF

Eq.4.1

where n represents total number bound FGF-1 molecules, m is the total protons attached
and MFGF is the mass of a single FGF molecule.

4.3.2.2 DelPhi Calculations
DelPhi V. 4r1.1,130,131 which applies non-linear Poisson-Boltzmann equation to
generate the potential surface of the protein, was used to model the electrostatic potential
around FGF-1 (PDB id: 1K5U) at the experimental conditions as described (pH 7.0, I =
100 mM). The structures were taken from the protein data bank (http://www.rcsb.org/).
The charges of amino acids on the protein were determined using Tanford’s sphericalsmeared charged model.132

4.3.2.3 Monte-Carlo Simulations
The MC technique with the Metropolis algorithm147 was used for generating
equilibrium states. The MC technique ensures that the system eventually reaches thermal
equilibrium for the oligomer-protein complex. Heparin was presented by a decamer of 6
units of acrylamidopropylsulfonate and 4 units of acylamide; this AMPS-AAm oligomer
has the same chain length and net charge as the well-known heparin pentasaccharide.19
The temperature chosen for the simulations was T = 300 K. The charges on the various
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residues were those appropriate to FGF-1 at pH 7.0 and protein was modeled as partially
coarse-grained.

4.4 Results and Discussion
4.4.1 Heparin facilitates formation of FGF-1 multimeric complexes
The ESI mass spectrum of FGF-1 (5 M) in the absence of heparin oligomers
showed no evidence of dimers or higher-order multimers (Figure 4.1). However, in the
presence of dp8 or dp10, at concentrations ranging from 1.25 to 25 M corresponding to
[FGF] / [Hp] ratio r = 4, 2, 1 and 0.2, formation of 1:1, 2:1 and 3:1 (FGF:heparin)
complexes were observed (Figure 4.1a and 4.1b). When FGF was in excess relative to
heparin, 3:1, 2:1 and 1:1 complexes were detected, but the 3:1 complex formation was
most prominent in the presence of dp10 (Figure 4.1b). On the contrary, the 1:1 complex
was detected as the most populated ionic species in the case of the excess heparinoid (at r
= 0.2).
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Figure 4.1: ESI mass spectra of FGF-1/heparinoid complexes at 100 mM
NH4CH3CO2, pH 6.8 (a) r ([FGF-1] / [dp8]) = 2, 1, 0.2 and 0. (b) r ([FGF] / [dp10]) =
4, 1, 0.2 and 0. The charge state distributions of free protein, 1:1, 2:1 and 3:1
complexes are presented gray, blue, pink and green labels, respectively.
The dependence of complex stoichiometry on the mixing ratio suggests a multiple
binding equilibrium with heparin as the host molecule. For excess heparin, the presence
of free protein indicates either that affinity is low, or that high affinity sites are fully
occupied. These results, however, do not reveal how such high and low affinity sites are
distributed among the heparin chains.
The formation of 3:1 complex, particularly favorable at high r (excess protein),
brings up the need to explain how the heparin oligomer chain can accommodate three
FGF molecules. The DelPhi image of FGF-1 (Figure 4.2), showing the 0.5kT/e
electrostatic potential contours, indicates a dominant positive patch at pH 7.0, I = 100
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mM. Even though the exact location of the bound Hp chain cannot be determined, it can
be assumed that highly negative heparin would avoid the negative domains of the protein.
Such predominant electrostatic effects make the classical “lock and key” interaction
unlikely. The immediate vicinity of the positive domain can be viewed as creating a
strong attraction basin for polyanions without forcing them into highly defined and thus
entropically disfavored conformations. This dynamic behavior notwithstanding, the FGFbinding site size on heparin of 4 contiguous units (~2 nm) as determined from dynamic
and static light scattering studies,134 would seem to indicate that dp10 (contour length 5
nm) could not realistically bind three FGF-1’s with hydrodynamic diameters of 4 nm,
particularly in a cis complex. However, heparin, a semi-flexible chain,10 can exhibit
local conformations in solution148 to facilitate FGF-1 binding from multiple directions ,
i.e., formation of a trans complex (as in Figure 4.2b and c).
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Figure 4.2: (a) Electrostatic potential contours (-0.5 kT/e (red) and 0.5 kT/e (blue))
generated around FGF-1 (PDB id: 1K5U) at 100 mM pH 7.0. Possible models for the
structural arrangements of the (b) 2:1 and (c) 3:1 complexes are presented.

Additional evidence for the arrangements of the 3:1 complexes can be deduced
from Monte Carlo simulations of the FGF-bound Hp-mimetic oligomer chain. Simulation
snapshots shown in Figure 4.3, indicate that only a small part of the polyanion interacts
with the protein at any instant. From this point of view, three FGF may be “bridged” by
dp10, in the sense that they are highly co-localized with transient interactions with the
oligoheparin overcoming intrinsic inter-protein repulsions.
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Figure 4.3: The MC snapshots of FGF and charged decamer residing at the FGF
binding site at pH 7.0 and I =10 mM. FGF is represented with the electrostatic
potentials at 0.5 kT/e, red and blue correspond to negative and positive protein
potentials via solutions of the nonlinear Poisson-Boltzmann equation. The frames
shown (a) through (f) are 25K MC steps apart and they are in the range of 225K to
350K MC steps (Courtesy of Daniel Seeman).

4.4.2 Higher sulfated chains promote formation of multimeric complexes of FGF-1
Heparin structure is immensely heterogeneous due to the seemingly random
placement of sulfate groups (Figure 4.4). Dp8 and dp10 fragments exhibit structural
polydispersity with respect to both total levels of sulfation and their distribution across
the polysaccharide backbone.
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Figure 4.4: Repeating disaccharide unit of heparin oligomers. The possible locations
for sulfate substitutions are shown in red. ( n is equal to 4 and 5 for dp8 and dp10,
respectively.)

Observation of different stoichiometric complexes with dp8 and dp10 indicated
existence of multiple biding sites with various levels of affinity for FGF-1. In order to
identify the structural features, i.e. degrees of sulfation of the dp8 and dp10 binders, the
mass distribution of bound dp8/dp10 was determined. Mass to charge ratio for the most
abundant peak of a protein/heparinoid complex (+7 for 1:1, +12 for 2:1 and +14 for 3:1)
was converted to neutral mass using Eq. 4.1, and the mass distribution of the bound dp8
and dp10 are presented in Figure 4.5 and 4.6. Since all analyses were performed in the
positive ion mode, each ionic species also contain 4-5 cations (NH4+). Therefore, shaded
boxes are used in Figure 4 and 5 to indicate the mass ranges for heparinoid species with
different extent of sulfation (the overlap is due to the uncertainty in the number of
cationizing agents attached to each polyanionic chain). We used Roepstorff-Henriksen
nomenclature (X,Y,Z)80 to present sequence distribution of dp8/10, in which X represents
number of saccharide, Y is the number of sulfate and Z is the number of acetyl groups.
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Figure 4.5: The mass distribution of the bound a) dp8 in the r = 0.2 and 1, b) dp10 in
the r = 0.2, 1 and 4 are shown. Blue trace represents the +7 charge states of the 1:1
complexes, pink trace is the +12 charge states of the 2:1 complexes and green trace
is the +14 charge states of the 3:1 complexes.

In Figure 4.5 (a), mass distribution of protein bound-dp8 molecules in 1:1 (blue
traces) and 2:1 (pink traces) complexes were plotted for r = 1 and r = 0.2. A comparison
of these two profiles indicates that protein bound dp8 chains carry 8 to 12 SO 3- groups.
In both cases, the 2:1 complexes were formed only on the highly sulfated chains (11 and
12 SO3- groups per chain). Low sulfated chains (with 8, 9 and 10 SO3 -), retained the
binding affinity for FGF-1, but they facilitated formation of only the 1:1 complex.
Increasing dp8 concentration (r = 0.2) shifted the complex equilibrium towards 1:1 and
the degree of sulfation in the 1:1 complex skewed towards higher sulfation, possibly
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reflecting the fact that the lower charge density heparinoids are capable of binding to
FGF-1 when their higher charge density counterparts became completely consumed.
Figure 4.5 (b) represents the mass distribution of protein-bound dp10 chains in
1:1 (blue traces) and 2:1(pink traces) complexes at r = 0.2, r = 1 and r = 4. In addition to
1:1 and 2:1 complexes, 3:1 complexes (green trace) are also observed at r = 4, and 3:1
complexes are formed on the chains containing 14 and 15 SO 3 - groups. The 2:1
complexes are formed in the intermediate range of sulfation (11 to 13 SO3-) and finally
the 1:1 complex contains low sulfated chains. Higher dp10 concentration (r = 1) raises
the number of available binding sites for FGF-1, as a result the ionic signal for the 3:1
complex is quite low, and the degree of sulfation in 2:1 and 1:1 complexes is skewed
towards higher sulfation, 12-15 and 10-14 SO3- groups, respectively. When dp10
concentration is in 5-fold excess over FGF-1 (r = 0.2), only the 1:1 complex formed, in
which low sulfated chains are replaced by the high sulfated dp10 chains (the number of
sulfation is varied from 11 to 15). These results could indicate that: (1) highly sulfated
chains are occupied first; (2) high sulfated chains have multiple binding sites (up to 3)
with various degrees of affinity for FGF-1; (3) low sulfated chains are capable of binding
to FGF-1; however the affinity is lower than highly sulfated ones.

4.4.3 When bulk stoichiometry leads to a significant amount of bound heparin, the
charge density of the free heparin is low relative to the initial heparin
In this work, we utilized mass spectrometric approach to evaluate importance of
heparin sulfation for FGF1-dp10 binding. While binding preferences of proteins towards
Hp have been generally determined by analyzing protein/Hp complexes,149,150 an
alternative approach to this question utilized monitoring differential depletion of small
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molecule ligand from the entire ensemble of heparinoid molecules upon addition of
binding partner.88 Figure 4.6 (a) and 4.6 (b) demonstrates bound and unbound dp10 mass
distribution for r = 1, r = 0.5 and r = 0.2, respectively. The calculation described for
Figure 4.5 was applied to obtain mass distribution of protein-bound dp10 species (Figure
4.6 (a)). Unbound (free) dp10 species appears at 1200 < m/z <1600 at +2 charge states
and m/z values were transformed to the mass distribution.

Figure 4.6: The mass distribution of the a) bound and b) unbound dp10 species at r
= 1, 0.5 and 0.2

Mass distribution of unbound dp10 extends beyond that of the protein-bound
dp10, because dp10 contains 11- 14 NH4+ adducts when they are free in solution, as
opposed to 4-5 NH4+ in the protein-bound form. The depletion of dp10 species was more
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pronounced at r =1, where the 2:1 ionic signal was more abundant and highly sulfated
chains (14 and 15 SO3 -groups) facilitated the complex formation. Moderate to low
number of sulfated groups were engaged in the formation of 1:1 complex (10 to 13 SO3-),
in which the majority of the binders carry 12 and 13 SO 3- groups. This observation is
clearly consistent with the Figure 4.6 (b): dp10 chains incorporating 13-15 sulfate groups
are almost completely depleted; therefore ionic signal from 10 to 12 sulfated species
becomes more abundant on a relative scale. The r = 0.5 presents a transition stage in that
the 2:1 complex ionic abundance decreased and sulfation distribution is skewed to higher
sulfation for the 1:1 complex. Similarly, depletion of the highly sulfated species is quite
evident at r = 0.5, as seen in Figure 4.6(b). Since dp10 concentration was quite high
relative to the protein at r =0.2, the depletion of the dp10 chains was minimal, and
protein-free dp10 spectra (r = 0) and r = 0.2 free regions are almost identical.
These results support the previous identification of highly sulfated species as
primary agents triggering formation of in the FGF-1 multimers. The heparin chains may
exhibit not only intra-chain heterogeneity, but also inter-chain diversity so that the chains
having same number of sulfates may not have the same distribution of sulfate groups.
The arrangement of the sulfate groups within these chains can occur in numerous ways
considering the possible locations in a disaccharide as represented in Figure 4.4. There
are 20 sites available for sulfation within dp10, and if these sites are assumed to have
equal probability of carrying a sulfate group; the possible ways to distribute sulfate
groups can be calculated by:
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where n is the total sites and k is the number of sulfate groups.

Figure 4.7: The number of possible structural arrangements depending on the
number of sulfate groups within dp10.

The results obtained by using Eq. 4.2 are presented in Figure 4.7. The number of
variations to distribute sulfate groups is lower in the highly sulfated chains; therefore, the
possibility of having equally distributed charges, i.e. “charge segments”, along the chain
is higher. As seen in Figure 4.6 (b), highly sulfated dp10 chains (carrying 14 and 15
sulfate groups) were completely depleted at r = 1, on the contrary dp10 chains carrying
10- 12 sulfate groups are more abundant on a relative scale. Structural variations are
higher for these chains; therefore the probability of having a “charge segment” is much
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lower. These observations could explain (1) the preferential binding between FGF-1
molecules and the highly sulfated chains, in which highly sulfated chains can provide
properly arranged charged domains for FGF-1; (2) the incapability of the low sulfate
chains to induce multimeric complexes of FGF-1 due to the decreased amount of “charge
segments”.

4.5 Conclusions
ESI-MS results suggested that the nature of the FGF- heparinoid interaction was
“promiscuous” in that both high and low sulfated chains could be involved in binding
events. Highly sulfated dp8 and dp10 chains are involved in multimer formation than
lower sulfated chains. When dp8/dp10 is excess, low sulfated binders are replaced with
highly sulfated ones in the 1:1 complex, which is a clear representation of the
competition between low and high sulfation in protein recognition. The formation of 3:1
complexes on highly sulfated dp10 chains also indicates a packed structure, in which
proteins could be bound with close proximity. Heparin induced multimerization of FGF
on the varying degree of sulfation could be an evidence that heparin oligomers
“concentrate” FGF molecules along the heparin chain; therefore the probability of the
receptor interaction could be increased. Furthermore, these studies emphasize the power
of ESI-MS to characterize protein interactions with the highly heterogeneous targets.
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CHAPTER 5
ELECTROSPRAY IONIZATION MASS SPECTROMETRY STUDY TO
REVEAL THE EFFECT OF HEPARIN CHAIN LENGTH ON ANTITHROMBIN
AND FACTOR XA COMPLEX FORMATION
Minsky, B. B.; Abzalimov, R; Dubin, P. L.; Kaltashov, I. A.
5.1 Introduction
Full-length heparin, low molecular weight heparins and small molecule heparin
analogs have been administered as anticoagulant drugs for decades; however, their
efficacies are reduced by the high risk of bleeding151 and the requirements of patientdependent dose administrations.152 Safer and more effective therapies can be achieved
through greater understanding of the way that heparin mediates antithrombin and
protease binding, which is a central inhibitory process in coagulation. However, the
accuracy of models for the binding of antithrombin and coagulation proteases is a matter
of controversy. In this study, we monitor complexation of antithrombin (AT) and
coagulation protease Factor Xa (FXa) in the presence of defined-length heparin (Hp)
oligomers using electrospray ionization mass spectrometry (ESI MS) in order to compare
the capabilities of various length heparin oligomers to induce binary (AT·FXa) and
ternary (AT·FXa·Hp) complexes.
Antithrombin, a natural anticoagulant in the blood, inhibits coagulation proteases,
predominantly thrombin and Factor Xa, by forming equimolar and stable complexes. 15378

155

Although this process occurs naturally in the blood, the binding process is extremely

slow. Heparin and heparan sulfate enhance the rate of antithrombin-thrombin/Factor Xa
complex formation by up to several orders of magnitude. 156 In both cases, heparin acts as
a catalyst, and therefore it is not necessarily a part of the final complex.33 The mechanism
of AT-protease binding has been suggested to follow two sequential events: (1) diffusioncontrolled formation of an encounter complex; (2) formation of a reaction-controlled
stable covalent complex.33,157 If heparin promotes the encounter complex, its role would
be basically confining two proteins on the same chain, so they have more time to interact.
This "approximation effect" is suggested for AT-thrombin binding.158 If heparin
modulates the reaction part, it would do so by inducing the conformational change on
AT: this mechanism is proposed for AT-FXa interaction (allosteric effect).159
The minimal heparin length required to promote the approximation effect is 18
monosaccharide units;158 whereas a specific pentasaccharide has been proposed to be
capable of activating AT towards Factor Xa160 as a result of an induced conformational
changes on AT (allosteric activation). This model has been challenged by recent studies
showing that binding to heparin chains of various length does not significantly change
secondary structure, but in fact enhances the conformational stability of AT, a stronger
effect observed with shorter heparin oligomers.161 The formation of encounter complexes
and an approximation effect have also been experimentally observed for AT-FXa in the
presence of longer chain heparins.162 Calcium ions have been shown to improve anti-FXa
activity with increasing Hp chain length. 163 Consistent with the approximation effect
model recent findings indicate that long chain heparins enhance AT-FXa binding, even in
the absence of calcium ions.164 In the crystal structure of Factor IXa, a crystal contact was
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observed with heparin pentasaccharide, which was interpreted as a possibility for longer
chain to form encounter complex.165
The anticoagulant activity of heparin was famously ascribed to a unique pentamer
carrying a rare 3-O-sulfate substitution,18 but many observations run counter to this yet
influential paradigm. Recent studies indicate that 3-O-sulfate substitution may not be
needed to promote allosteric activation of AT. 166 Less complex polyanions, such as,
sulfated dextran167 and sulfated lignins,168 can imitate Hp function in AT-FXa binding.
The putative interaction between AT and the high-affinity binding specific
pentasaccharide embodied directionally specific short-range interactions (H-bonds and
salt bridges).17-19 This concept of specificity essentially incorporates a frozen state of ATbound heparin despite the intrinsic flexibility of oligoheparins. 9 Furthermore, nonmonotonic salt dependence, difficult to rationalize on the basis of short-range attraction
alone, has been observed for AT and low molecular weight and full-length heparin
interactions,28 as for other protein-polyelectrolyte systems.51 These observations highlight
the significance of the combinations of short-range attractions and long-range repulsions
between the negatively charged heparin and the highly anisotropic protein surface
charges,28,44,51 and introduce a nuanced view of specificity that takes into account the
charge complementarity between the protein surface and the polyanion.31
The stoichiometry and the mechanistic interpretations of AT-FXa binding have
primarily evolved from crystallography studies, 23,169 involving short heparin analogs. In
this way, the effects of the intrinsic heterogeneity of biologically relevant heparin chains
could be overlooked. Therefore, in order to investigate the AT-FXa complex
stoichiometries, we use a set of well-defined heparin oligomers, whose chain lengths
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range from hexa- to icosasaccharide. Electrospray ionization mass spectrometry (ESI
MS) serves this purpose exceptionally well by providing remarkable structural details and
revealing complex stoichiometries.

5.2 Experimental

Human α-AT (MW = 57.8 kDa), was purified from human plasma using heparin
affinity chromatography, generously donated by CSL Behring (Marburg, Germany),.
Heparin oligomers (dp6, dp8, dp10 and dp20) and native heparin were provided by John
T. Gallagher (Iduron, Manchester, UK). Human Factor Xa, which is a mixture of α (45.3
kDa) and β (43.3 kDa) subforms, was purchased from Haematologic Technologies, Inc
(Vermont, USA). Factor Xa(β) is formed as a result of autoproteolysis of Factor Xa(α),
and both subforms have equal roles in coagulation. 170 Protein and heparin oligomer
solutions for ESI MS analysis were prepared in 150 mM ammonium acetate at pH 7.0 to
final concentrations of 1.8 μM for AT and 1.8 μM for FXa, and 7.5 to 15 μM for heparin
oligomers. All binding experiments, both in the absence and in the presence of heparin
oligomers, were completed within an hour after mixing of the components. ESI MS
experiments were performed with a QStar-XL hybrid quadrupole-time-of-flight MS with
a nano-ESI-source (AB Sciex, Toronto, Canada) and the measurements were performed
using closed (2 μm id) glass nanospray capillaries (New Objective, Woburn, MA).
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5.3 Results
5.3.1 Short heparin oligomers induced formation of AT·FXa binary complex

Figure 5.1A shows the ESI mass spectra of AT-FXa in the presence of dp10 with
concentrations varying from 0 to 15 μM. In the absence of dp10, the ionic signal
representing AT·FXa complexes is in very low abundance, whereas free AT and free FXa
species contribute to the ionic signal significantly.
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Figure 5.1: ESI mass spectra of AT (1.8 μM) and FXa (1.5 μM) in the absence and
presence of Hp oligomers at 150 mM ammonium acetate, pH 7.0. A) The
dependence of AT and FXa binary complex formation to dp10 concentration. B)
AT and FXa complex formation with various lengths heparin oligomers ( dp6, dp8
and dp10) using 15 μM of oligomers. The notations represent: Bα = AT + FXa (α ) =
103.3 kDa and Bβ = AT + FXa (β ) = 101.3 kDa

In the presence of dp10, ESI MS spectra provide clear evidence for the formation
of 1:1 AT·FXa complexes. Raising dp10 concentration from 0 to 15 μM leads to a
progressive increase in AT·FXa complexes and a decrease in free FXa ionic species. In
the presence of dp10, the resultant complex was assigned to a mass distribution with a 1:1
AT·FXa stoichiometry and dp10 was not detected as a part of the complex, at least with
the standard deconvolution methods. Using 15 μM dp10 concentration results in optimal
ratio of AT·FXa to free AT and FXa ratio; thus this concentration was used to determine
complex stoichiometries with even shorter heparin oligomer chains. As seen in Figure
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1B, similar binding patterns were observed between AT an FXa in the presence of 15 μM
dp6, dp8 and dp10, and there was no evidence for the ternary AT·FXa·dp6 and
AT·FXa·dp8 complexes.
In order to provide further evidence for the absence of ternary complexes, dp10
free and dp10 present spectra are overlaid in the AT·FXa complex region (4600 < m/z <
5200), and peak widening was observed in the dp10 present spectrum (Figure 5.2A). The
wider peaks could be an indication of the presence of AT·FXa·dp10 complexes; therefore
these peaks were deconvoluted using Gaussian fittings to investigate any possible
contributions from AT·FXa(α)·dp10 and AT·FXa(β)·dp10 complexes. The widths of
these complexes were estimated relative to the AT·dp10 complex, which is already
present in the spectra. As seen from the Figure 5.2B, there is a small contribution from
AT·FXa·dp10 complexes, and this contribution does not exceed 20% of the total binary
complex.
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Figure 5.2: A) Superimposition of AT-FXa and AT-FXa-dp10 spectra in the binary
complex region. B) Gaussian fittings to investigate the contributions of ternary ATFXa-dp10 complexes to the binary complex

5.3.2 Longer chains induce formation of higher order AT-FXa complexes (dp20 and
native heparin chains

Short heparin chains (dp ≤ 10) facilitated AT-FXa interaction, and intriguingly
these chains were dissociated from the resultant complex in the course of the
experimental time scale. However, longer heparin chains (dp 20) were capable of
inducing AT·FXa(α)·dp20 and AT·FXa(β)·dp20 complexes, corresponding to 107.3 kDa
and 109.3 kDa complexes, respectively (Figure 5.3A). Gaussian fittings were generated
using the peak shapes of the AT·dp20 complex and the resultant peaks matched with the
AT·FXa(α)·dp20 and AT·FXa(β)·dp20 complex peaks. This analysis distinctly
demonstrates that AT·FXa complexes are absent from the spectra (Figure 5.3B).
85

Figure 5.3: A) ESI mass spectra of AT (1.8 μM) and FXa (1.5 μM) in the presence of
heparin dp20 (7.5 μM) at 150 mM ammonium acetate, pH 7.0 representing ternary
AT-FXa(α )-dp20 ( 109.3 kDa) and AT -FXa (β )-dp20 (107.3 kDa ) complexes. B)
Gaussian fittings to validate ternary AT-FXa(α )-dp20 and AT -FXa (β )-dp20
complexes.
The concentration of dp 20 used in this experiment was 7.5 μM, and this amount
was sufficient to induce the formation of AT·FXa·dp20 complexes and deplete the free
FXa components notably. Similar complex formation and depletion patterns were
obtained using a 15 μM concentration of shorter heparin oligomers (dp ≤ 10). In addition,
the relative abundance of free AT as a function of heparin oligomer chain length is
significantly lower with dp20 compared to the shorter heparinoids (dp ≤ 10).
AT and FXa binding, in the presence of native (un-fractionated) heparin
represents the most challenging case. Figure 5.4 shows the addition of ~2.4 μM native
heparin at the same conditions used for shorter heparinoids in AT and FXa binding
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experiments. Even though the relative abundances of free AT and FXa components have
been substantially decreased, the immense structural heterogeneity of native heparin
limits any meaningful interpretations for the probable AT-FXa complexes in the m/z
region beyond 4500. Nonetheless, this highly complex spectrum suggests promising
future studies to distinguish higher order AT-FXa complexes on native heparin chains
with more sophisticated ESI MS methods, such as limited charge reduction on FTICR
MS.171

Figure 5.4: Superimposition of ESI mass spectra of AT (1.8 μM) and FXa (1.5 μM)
in the absence (black trace) and presence of native heparin (~2.4 μM) (red trace) at
150 mM ammonium acetate, pH 7.0.
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5.4 Discussion

ESI MS has advantages over other biophysical techniques to determine the
stoichiometry of the multi-protein complexes, which exist in solution under
equilibrium.172 In this study, we have investigated the effect of heparin chain length on
mediation of complex formation between AT and FXa, which is an inhibitory event in
coagulation. In this diffusion-controlled macromolecular reaction, an AT·FXa·Hp
encounter complex forms prior to reaction.173 At the final step of the reaction, an AT·FXa
covalent binary complex forms174,175 and heparin dissociates from the complex. Our ESI
MS results demonstrated that the formation of the AT·FXa binary complexes is greatly
enhanced in the presence of short heparin oligomers (dp ≤ 10). The AT·FXa binary
complex signal was correlated with the concentration of heparin oligomer, as also
suggested by the previous findings.176 In our studies, Hp oligomers were not detected as
a part of the final complex, especially with dp6 and dp8, which could indicate that short
heparin oligomers catalyzed the encounter and reaction completed faster. This
observation could be in accordance with recent studies, in which short heparin oligomers
were proven to be more efficient in catalyzing AT-FXa binding by improving the
conformational stability of AT.161
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Figure 5.5: Proposed the reaction steps in diffusion-controlled AT, Hp and FXa
interactions.

In the presence of dp20, ESI MS clearly demonstrates that dp20 facilitates the
formation of stable ternary AT·FXa·dp20 complexes. AT·FXa binary complexes were
certainly absent from the spectra, as confirmed by the deconvolution analysis. One
possible reason is that dp20 binds simultaneously to AT and FXa. This “reduction in
dimensionality effect”33 is consistent with the previous observations for AT and thrombin
interactions.158,162 While proteins are bound on the same chain, they might spend more
time interacting and this might delay the formation of final binary covalent AT·FXa
complex.

Figure 5.6: Crystal structures for (a) AT-FXa-pentasaccharide and (b) ATThrombin-heparin (18 monosaccharide length)

89

The other possibility is that dp20 exhibits higher affinity towards AT; therefore it
does not dissociate from AT even after the reaction stage is completed. The higher
affinity of dp20 compared to shorter heparin oligomers can be qualitatively assessed from
the ESI MS spectra by the comparison of the relative abundance of free AT or ATheparinoid complex as a function of heparin oligomer chain length. The most dramatic
difference can be seen in the case of dp20 binding, in which the AT·dp20 complex
exhibits higher relative abundance compared to the shorter chains, even though the
concentration of dp20 is half that of the shorter heparinoids. Specific Hp chains that
facilitate the AT-FXa interactions are the main interest in pharmaceutical applications;
however, the structural heterogeneity is such that the resolution of our experiments was
not sufficient to determine the specific heparin oligomer species.

5.5 Conclusions
Short Hp chains (dp ≤ 10) promoted binary AT·FXa complexes and they most
likely have improved the conformational stability of AT towards FXa to facilitate the
reaction. On the contrary, dp 20 induced ternary AT·FXa·dp20 complexes, possibly by
binding simultaneously to AT and FXa. Furthermore, higher affinity between AT and
long heparin chains could be the reason that dp20 stays in the ternary complex longer.
Native heparin chain could promote formation of higher order AT-FXa complexes,
(possible 4:1) and this observation could be further supported by the future studies using
limited charge reduction method in FTICR MS. This study also demonstrated (for the
first time) the capability of ESI MS to resolve the complex stoichimetries between AT
and FXa in the absence and in the presence of heparin oligomers.
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CHAPTER 6
ANTITHROMBIN AND FULL-LENGTH HEPARIN COMPLEXES DETECTED
ON FTICR MS BY LIMITED CHARGE REDUCTION
Abzalimov, R.; Minsky, B. B.; Kaltashov, I. A.
6.1 Introduction
The preeminent challenge in the characterization of protein-heparin interactions is
the immensely polydisperse heparin structure, which limits the application of various
analytical techniques. Thus, the most common approach is to use heparin oligomers with
a reduced-heterogeneity in protein interactions. Even though heparin oligomers have
provided insights on the protein binding, the structural properties of these oligomers
deviate from the biologically relevant full-length, “native” heparin (Hp). Electrospray
ionization mass spectrometry (ESI MS) has emerged as a fundamental technique to study
heparin oligomers and detect their non-covalent complexes; however correct mass and
charge assignment is a major obstacle for the highly heterogeneous systems, especially
for full-length heparin-protein complexes. We approached this problem using a recently
evolved technique, limited charge reduction, in order to determine the complex
stoichiometries between antithrombin (AT) and full-length heparin.
Characterization of native heparin-protein complexes have been achieved using
various analytical tools, such as light scattering,134 analytical ultracentrifuge,125 size
exclusion chromatography.177 Even though these techniques provide size distributions of
macromolecular complexes, deducing complex stoichiometry can be challenging due to
the coexistence of multi-protein complexes in solution. In addition, these techniques
provide average solution properties and do not provide detailed structural information.
91

ESI MS appears as a significant tool for the detailed structural information of the proteinheparin complexes; however native ESI MS has not been fully implemented in this field
so far. The applications have been limited to relatively homogeneous and shorter length
heparinoids and their complexes with proteins. 88,178-181
The enhanced applicability of the short heparin analogs has generated concerted
efforts to define the specific heparinoid structure in protein binding. 18 However, this
reductionist approach not only deviates from biological relevance, but also ignores the
polyelectrolyte properties of heparin. In heparin-protein binding, long-range electrostatic
forces and chain dynamics contribute significantly to the protein recognition and
selectivity process.139 Therefore, there is a need for improved analytical tools to
characterize native heparin-protein complexes in more detail and obtain structural
information. ESI MS can be utilized for this purpose, but the challenges associated with
the immense heterogeneity need to be addressed.
A recently developed technique, limited charge reduction, mass-selects a narrow
subpopulation of the ionic species in the highly heterogeneous spectra, which are then
subjected to electron capture reactions to induce formation of well-defined charge
ladders. The resulting charge state “ladder” can be used to calculate the mass of isolated
complex ions. This method was successfully implemented to analyze highly
heterogeneous systems, such as

glycosylated proteins182 , protein aggregates183 and

protein multimers.184 AT-Hp interactions possess a great deal of interest due to the
clinical usage of heparin in anticoagulation, but the studies so far have been greatly
focused on the synthetic and short heparin mimetics to modulate AT binding. 168,185,186
The challenges associated with the heterogeneous native Hp can be overcome using
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limited charge reduction to determine the AT-Hp complex stoichiometries in near
physiological conditions.

6.2 Experimental
Human α-AT (MW = 57.8 kDa) was generously donated by CSL Behring
(Marburg, Germany) and was purified from human plasma using heparin affinity
chromatography. Full-length “native” heparin (Hp) was provided by John T. Gallagher
(Iduron, Manchester, UK). AT and Hp solutions for ESI MS and FTICR MS analysis
were prepared in 150 mM ammonium acetate to final concentrations of 1.8 μM for AT
and 0.044 g/L, ca. 2.4 μM for Hp. Both nano-ESI Qstar-MS and FTICR MS show that
the concentration of AT should not exceed 1.5 μM to prevent formation of AT multimers
prior to Hp addition. ESI MS experiments were performed with a QStar-XL hybrid
quadrupole-time-of-flight MS with a nano-ESI-source (AB Sciex, Toronto, Canada) and
the measurements were performed using closed (2 μm id) glass nanospray capillaries
(New Objective, Woburn, MA). Protein ion charge reduction was carried out with a
SolariX 70 (Bruker Daltonics, Billerica,MA) Fourier transform ion cyclotron resonance
(FTICR) MS. Ion isolation was done in the collision cell (up to 2 seconds of
accumulation time) and electron capture was applied is in the ICR cell. Molecular weight
distribution of full-length heparin was determined by SEC-MALLS (Wyatt) using
TOSOH SW3000xl column to elute 1 g/L heparin sample with 0.1M NaCl. AT-Hp
complexes were also determined by SEC using TOSOH SW3000xl column (mobile
phase: 150mM ammonium acetate, pH 7.0).
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6.3 Results and Discussion
6.3.1 AT-native Hp complexes were obtained using native ESI MS and SEC
AT is a highly glycosylated protein (58 kDa) with an approximately 15%
carbohydrate content by weight.187 ESI mass spectrum of AT and native Hp indicates free
AT monomer and AT-Hp complexes which appear in the range of 4500 < m/z < 6500
(Figure 6.1a). There are two distinct regions representing AT-Hp ionic species; however
both AT glycosylation and immense Hp structural heterogeneity give rise to a highly
complex and unresolved mass spectrum. In this case, it is not possible to determine the
exact mass and charge state distributions of these species due to overlapping ionic peaks
representing different charge states.
More evidence for the formation of AT-Hp complexes comes from SEC profiles
as shown in the inset of Figure 6.1b. SEC results shows that approximately 50 % of AT
monomer are depleted in the presence of Hp, and AT-Hp complexes form as shown by
the appearance of the early eluting peak. The complex peak has a broad width, which can
designate unresolved and various size AT-Hp complexes. Furthermore, the elution profile
of the native heparin on SEC-MALLS demonstrated that the native heparin chains have
an average mass of 18 kD with a 1.1 polydispersity index (Figure 6.1c). Both SEC and
native ESI MS evidently show the formation of multiprotein complexes of AT and Hp,
with a better resolution in ESI MS; however the limited charge reduction method is
certainly needed to resolve the exact complex stoichiometries.
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Figure 6.1: (a) ESI mass spectrum of AT (1.8 μM) and native Hp (0.044 g/L, ca. 2.4
μM) acquired using nano-ESI Qstar-MS (at 150 mM Ammonium acetate, pH 7.0).
(b) AT (0.4 g/L) and native Hp (0.2 g/L) complexes detected on SEC (c) Elution of
native heparin on SEC-MALLS.

6.3.2 Correct mass assignment of the AT-Hp complexes was achieved by limited
charge reduction
AT alone and AT-Hp mixture were also acquired on FTICR MS; however transfer
optics of FT-ICR MS was optimally tuned to detect ions at higher m/z range ( >4000).
Therefore, the intensity of the ionic species that represents AT-Hp complexes was more
abundant in FTICR MS than nanospray ESI MS. Protein self association was not
observed in the absence of Hp and the complex peaks were still unresolved due to the Hp
polydispersity and overlapping charge states.
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Figure 6.2: ESI mass spectrum of AT (1.8 μM) and native Hp (0.044 g/L, ca. 2.4 μM)
acquired using FTICR MS (at 150 mM Ammonium acetate, pH 7.0).
In the process of partial charge reduction, an isolated fraction of the Z+ charge
state ions is mass selected in the collision cell width w0. When these selected ions are
exposed to electron irradiation, they should produce charge reduced peaks and the widths
can be assigned to w=w0*(Z/Z-K) on the m/z scale, where K represents the number of
captured electrons. This approach was tested with the selection of m/z = 4580 (Figure
6.3a) and m/z = 4740 (Figure 6.3b) and they both showed that the equation accurately
estimates the widths of the charge reduced peaks (fitted with Gaussians in blue) based on
the defined widths of isolated peaks (fitted with Gaussians in black). Deconvolution
analysis reveals the mass distributions, which are ~73,180 Da in (a); ~75,820 Da in (b),
corresponding to AT·Hp (1:1) complexes. Therefore, it is quite reasonable to consider
this method for reliable identification of charge reduced peaks in more challenging cases,
which is shown in Figure 6.3c. The selection of m/z = 5200 yield two distinct
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distributions: (1) 88, 489 Da (green trace), which correspond to AT·Hp2 (1:2) species, (2)
135,510 Da (pink trace) which is assigned to AT2·Hp (2:1) complexes.

Figure 6.3: The results of partial charge reduction of mass-selected AT-Hp complex
populations. Insets represent the convoluted mass distributions of the detected
complexes.

The mass distribution of Hp molecules in the AT·Hp complexes with 1:1
stoichiometry are detected as 15 and 17 kDa (Figure 6.3a and 6.3b). On the contrary, Hp
mass is 19 kDa in the AT2 ·Hp complex (2:1) indicating that two AT molecules are able
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to bind to long Hp chains, which are approximately 33-mer (as the average mass of a
disaccharide is assigned to 571 Da10). Intriguingly, AT·Hp2 (1:2) complexes were
observed (Figure 6.3c), in which the total mass of bound two Hp chains are in the range
of 25 to 30 kDa.
Multiple heparin oligomer binding to AT has also been observed with shorter
chains. Figure 6.4 shows ESI mass spectra of AT-dp10 complexes with increasing dp10
concentration from (a) to (c), in which a progressive increase in the dp10 to AT bulk ratio
leads to the formation of AT·(dp10)2 and AT·(dp10)3 complexes. Multiple dp10 bindings
were achieved by using more than 25-fold higher concentration of dp10 over AT. On the
contrary, AT·(Hp)2 complexes were observed when native Hp molar ratio was 1.6-fold
excess over AT. This may indicate that the probability of finding the selective AT
binding domain is higher with the native Hp chains.
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Figure 6.4: ESI mass spectra of AT (~1 μM) and dp10 with dp10/AT mixing ratio (a)
10, (b) 25 and (c) 50 at 150mM ammonium acetate, pH 6.8. Panel (d) shows the
relative abundances of AT· (dp10)0, AT· (dp10), AT· (dp10)2 and AT· (dp10)3
complexes with respect to bulk mixing ratio.

6.4 Conclusions
Unresolved ESI mass spectra of extremely heterogeneous AT and native Hp
complexes were successfully analyzed by mass-selecting narrow ionic subpopulations
followed by limited charge reduction in the gas phase. The resulting charge state
“ladders” were used to calculate the mass of isolated protein ions; thus AT·Hp (1:1),
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AT·Hp2 (1:2) and AT2·Hp (2:1) stoichiometric complexes were detected. Relatively
shorter heparin chains were involved in 1:1 and 1:2 complexes, whereas longer Hp chains
were able to induce 2:1 complex formation. This study indicated that the limited charge
reduction method, complementary to native ESI MS, can be effectively used to obtain
structural information from highly heterogeneous complexes of biopolymers.
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CHAPTER 7
INHIBITION OF ANTITHROMBIN AND BOVINE SERUM ALBUMIN NATIVE
STATE AGGREGATION BY HEPARIN

Minsky, B. B.; Zheng, B.; Dubin, L. P., Inhibition of antithrombin and bovine serum
albumin native state aggregation by heparin. Langmuir 2013
7.1 Abstract
Protein native state aggregation, a major problem in pharmaceutical and
biological processes, has been addressed pharmacologically by the addition of proteinbinding excipients. Heparin (Hp), a highly sulfated polysaccharide, interacts with
numerous proteins with moderate to high affinity, but reports about its effect on protein
aggregation are contradictory. We studied the pH dependence of the aggregation of
antithrombin (AT) and bovine serum albumin (BSA) in the presence and absence of
heparin. High-precision turbidimetry showed strong aggregation for both AT and BSA in
I = 10 mM NaCl, conditions at which electrostatically-driven Hp binding and
aggregation both occur, with more obvious aggregation of heparin-free AT appearing as
larger aggregate size. Aggregation of AT was dramatically inhibited at Hp: protein 6:1
(mole ratio); however, the effect at 0.5:1 Hp: protein was greater for BSA. Frontal
analysis capillary electrophoresis showed a much larger equilibrium association constant
Kobs between Hp and AT, in accord with the onset of Hp binding at a higher pH; both
effects are explained by the higher charge density of the positive domain for AT as
revealed by modeling with DelPhi. The corresponding modeling images showed that
these domains persist at high salt only for AT, consistent with the 160-fold drop in Kobs at
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100 mM salt for BSA-Hp binding. The smaller inhibition effect for AT arises from the
tendency of its uncomplexed monomer to form larger aggregates more rapidly, but the
stronger binding of Hp to AT does not facilitate Hp-induced aggregate dissolution which
occurs more readily for BSA. This can be attributed to the higher density of AT
aggregates evidenced by higher fractal dimensions. Differences between inhibition and
reversal by Hp arise because the former may depend on the stage at which Hp enters the
aggregation process and the latter on aggregate size and morphology.

7.2 Introduction
The effect of heparin (Hp) on protein aggregation would appear from the
literature to comprise both promotion and inhibition. These conflicting results could
reflect the problem of comparing different proteins with different levels of Hp affinity
and different aggregation mechanisms, both dependent on solution pH and ionic strength.
Native state aggregation could facilitate the study and interpretation of Hp effects,
because protein surface is better conserved and formation of unfolded states minimized.
Native state protein aggregation is driven by electrostatics, and the protein surface charge
anisotropy regulates protein self-association mechanisms. Electrostatics also controls Hpprotein binding to understand its effects on aggregation. There is a need to explain the
possible linkage between electrostatically driven native state aggregation and Hp-protein
binding. It is of interest to establish whether this relation holds for “heparin-binding”
proteins which exhibit different Hp-affinities, such as antithrombin (AT) and bovine
serum albumin (BSA). Therefore, we studied the native state aggregation of AT and BSA
and the roles of Hp in both aggregation and disaggregation processes, using ionic strength
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(I) and pH as a probe to investigate protein self-association mechanisms and Hp binding
affinities.
The detection of GAGs in deposits of fibrillar aggregates in amyloid diseases
initiated a number of conflicting hypotheses about the promotion/inhibition of the
aggregation of amyloid forming peptides and proteins in the presence of GAGs. The
enhancement of gelosin aggregation by heparin (Hp) was correlated with its sulfate
content and MW.188 Both Hp and CS (chondroitin sulfate) appeared to promote Aβ
peptide aggregation.189 On the other hand, while p25-α aggregated in the presence of
stoichiometric amounts of low MW Hp (10-14 monosaccharides), excess Hp diminished
its aggregation.190 Hp induces aggregation/ fibril formation of some proteins under
certain conditions, but may have more ambiguous or even benign effects, depending on
conditions, as observed for the prion protein.191,192 Injection of low molecular weight
heparin suppresses AA amyloid deposition in mice193 , and even when fibrils are
promoted by Hp are less toxic than the earlier forms of aggregates. 189,194-196 Finally,
inhibition of Aβ aggregation is reported for GAG-mimetic sulfated glycopolymers.197
These conflicting reports of Hp effects on amyloidogenesis may arise because the
point at which Hp enters the aggregation process can vary and is often not well defined.
This suggests that effects of Hp could be better understood with systematic studies with
folded proteins that include elucidation of self-aggregation mechanisms and identification
of the aggregation stage influenced by Hp. The self-aggregation of folded proteins is
mostly studied under “accelerated” conditions, such as high temperature 198 and low
pH;199-202 however these conditions generally lead, either intentionally or fortuitously, to
formation of intermediate states of the native structure, and the contribution of these
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states to the aggregation processes could be difficult to evaluate. 203 The two proteins
chosen for study here, AT and BSA, are examples of this; as both of them are commonly
studied at elevated temperatures.204-208 In contrast, the influence of Hp on native state
aggregation can be more amenable to modeling;209 therefore consistent with general
rules; because the hydrated protein surface is retained, and formation of intermediate
states can be minimized. The charge distribution on this surface, which plays a central
role in inter-protein interactions,124,133 is controlled by protein structure and pH.
Although native state protein aggregation is most readily seen at pH ~ pI
(“isolectric precipitation”), its suppression by added salt indicates the primacy of
electrostatic attraction.210 The central role of inter-protein surface interactions makes such
aggregation amenable to colloid models, in which the aggregation kinetics could
determine the aggregate structure. Aggregation follows formation of clusters from
monomers, and growth could follow particle-cluster or cluster-cluster, and formation of
these could be limited by diffusion.211 As shown in previous work,

22,25

protein charge

anisotropy dictates the balance of attractive and repulsive electrostatic interactions that
leads to one or more of the preceding aggregation mechanisms, which then control
aggregate structure. The charge anisotropy of proteins also controls their interactions with
Hp,31 and this suggests an implicit linkage between heparin-suppression and electrostatic
aggregation.209,210 For example, Hp inhibits native state aggregation of BSA and BLG,
with the inhibitory effect depending on charge-induced Hp-protein binding affinity.209
Beyond affinity, the stage at which Hp enters the aggregation process plays an important
role: inhibition of the aggregation of native state insulin seems to be enhanced when Hp
is added after aggregation has begun.210 The availability of Hp-binding domains is
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evidently subject to alterations in protein conformation. 212 In the present work, we avoid
contributions of protein unfolding by selection of conditions and proteins by on two
stable proteins, AT and BSA.
Heparin-protein binding affinity arises principally from polyelectrolyte-protein
electrostatic interactions,44,45 for which different models have been widely applied. One
model, inspired by theories for the salt dependence of oligolysine-DNA interactions,46,47
has also been applied to DNA-protein binding. The linear dependence of log Kobs
(equilibrium association constant) on log I (ionic strength) is consistent with a purely
entropic

Gobs which arises from the release of DNA counterions. However, directly

replacing oligolysines with proteins fails to consider the influence of protein charge
anisotropy.48 Nevertheless, extension of this treatment to Hp-protein binding yields a
physically realistic value of Hp structural charge density deduced from measured
dlogKobs / dlog I.49 On the other hand, many polyelectrolyte-protein systems show clearly
different salt dependence, more consistent with Debye-Hückel screening.44,50 This model
takes into account protein charge anisotropy, and effectively explains for the nonmonotonic salt dependence seen when polyelectrolytes (e.g., heparin) bind to proteins
with net charge of the same (i.e. negative) sign, through a domain of opposite (i.e.
positive) charge. This domain is best identified through representation of protein charge
calculations.51 Therefore, it is possible to account for the observed salt dependence of
protein-Hp binding by using specific models of heparin binding along with quantitative
protein visualization.28,51
The way in which Hp inhibits protein aggregation depends on Hp-protein binding
affinity, and the stage at which Hp enters the aggregation process. The ability of Hp to
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reverse aggregation depends also on aggregate structure. Resolution among these effects
has not been achieved because variables such as pH and ionic strength influence both the
mechanism and rate of aggregation, and the interaction of Hp with either aggregates or
free proteins. Protein charge anisotropy could in fact enhance both inter-protein and Hpprotein interactions. Systematic studies of pH and ionic strength effects on appropriately
selected aggregating and heparin-binding proteins are needed to elucidate these primarily
electrostatic effects. Also, further insight into the effect of heparin on protein solubility
could help guide the extensive but largely empirical use of polyelectrolyte precipitation
for protein purification.213-215
In order to elucidate the way in which the anti-aggregation effect of Hp is
influenced by protein self-association and Hp affinity, we examine two Hp-binding
proteins, Hp-cognate AT and non-cognate BSA. The literature clearly indicates larger
rates of aggregation for AT than for BSA, 205 although perspectives on their mechanisms
of aggregation differ.205,216 In our work, native states have been preserved; therefore the
behavior of the proteins is determined by its (hydrated) surface For this reason, general
rules about aggregation (e.g. “isoelectric precipitation”) can be put forward, in contrast to
unfolding aggregation in which any or all residues may contribute to a wide variety of
interactions involving many intermediates. We used high-precision turbidimetry to assess
both aggregation rates and Hp-affinity, and dynamic light scattering (DLS) to determine
the size and the relative intensity of the aggregates as a function of pH and ionic strength.
The fractal dimensions of the respective aggregates were measured by static light
scattering. Electrostatic protein modeling was used to visualize domains of positive
charge and to rationalize both aggregation and Hp-binding.
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7.3 Experimental
7.3.1 Materials
Human recombinant AT (ATyrn, 58 kDa, pI ~ 5.0) was generously donated by
GTC Biotherapeutics (Framingham, MA). Bovine Serum Albumin (BSA, 66 kDa, pI ~
4.9) and Heparin (Hp), with nominal MW 14 kDa, were purchased from Calbiochem and
Sigma, respectively.

7.3.2 Methods
7.3.2.1 Turbidimetry
High-precision turbidimetry was performed using a Brinkman PC800 digital
display probe colorimeter equipped with a 1cm path length probe (at 420 nm), integrated
into a system of our own design which is programmed for (1) automated constant
delivery of selected titrant volume via a 2 mL Gilmont microburette at selected rates of
addition, (2) selection of the number of percent transmittance (% T) and pH readings to
be averaged, and (3) choice of the terminal pH. The data were reported as τ = 100 - %T,
which is unitless and linear with the turbidity over a certain range of transmittance. AT
(0.25 g/L, 10 mL total volume) and BSA (1g/L, 10 mL total volume) solutions were
prepared at desired NaCl concentrations (10-50 mM), filtered (0.22 μm Millipore), and
titrated with either 0.1 N HCl or 0.1 N NaOH. AT-Hp and BSA-Hp mixtures were
prepared by 1:1 v/v mixing of AT/BSA and Hp stock solutions (0.5 g/L) at a noninteracting pH 8.5 (± 0.2). All measurements were done at ambient temperature. The
precision in the volume of titrant added is typically ±2 ppt (0.2 %). The ability to average
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multiple readings leads to transmittance measurement with a precision of 0.1 %T (±1
ppt).

7.3.2.2 Dynamic Light Scattering (DLS)
DLS measurements were made after filtration (Millipore 0.22 μm) using a
Malvern Instruments Zetasizer Nanosystem ZS, operating at 173º scattering angle with a
633 nm He−Ne laser, at 25 °C. The measurement duration was 10-12 s. The distributions
of the mean apparent translational diffusion coefficients (DT) were determined by fitting
the DLS autocorrelation functions using nonnegative constrained least-squares (NNLS).
The distribution of apparent hydrodynamic diameters Dh was obtained from the
distribution of mean apparent translational diffusion coefficients (D T) via
Dh

2 kT
6

Eq. 7.1

DT

where k is the Boltzmann constant and η is the solvent viscosity, taken as that of water.
Sample transfer and automated optimization steps result in a delay of 2−3 min. between
initial pH adjustment and the first measurement.

7.3.2.3 Static Light Scattering (SLS)
SLS experiments were performed using a BI-200 SM goniometer and BIC-2030D
photon counting system (Brookhaven Instruments Inc.) with an Omnichrome Ar ion laser
(100 mW, λ = 488 nm) at ambient temperature, 25 °C. The scattering intensity was
measured as a function of scattering angle between 45 and 130°. Fractal dimensions (D f)
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were extracted from angle dependence in the high-q limit via linearization of the
scattering data using the relation:
I (q )

q

Df

Eq. 7.2

where I(q) is the scattering intensity and the scattering vector q = (4πn/λ) sin (θ/2), with n
the refractive index of the fluid, λ the wavelength, and θ the scattering angle. The radius
of gyration (Rg) was obtained using Guinier relation at relatively low-q region:
2

ln( I ( q )

ln( I ( 0 )

2

q Rg

Eq. 7.3

3

7.3.2.4 Computational Methods
DelPhi V. 4r1.1130,131 was used to model the electrostatic potential around the
protein as a function of ionic strength. PDB id is 3V03 and 2B4X were taken from
protein data bank (http://www.rcsb.org/) for BSA monomer and AT monomer,
respectively. The charges of amino acids on the proteins were determined using the
spherical-smeared charged model put forward by Tanford.132

7.4 Results
7.4.1 Protein aggregation: effects of pH
7.4.1.1 AT shows higher turbidimetric rates of aggregation
Figure 1 shows the increase in 100 - %T in the range 4 < pH < 7 upon addition of
acid to 1 g/L BSA in 10 mM NaCl. A reduced concentration of 0.25 g/L was used for the
more rapidly aggregating AT in order to maintain 100 - %T < 20. In this range 100 - %T
is linear with the true turbidity τ = - log T, and can be most readily identified with the
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accumulation of soluble aggregates.217,218 The pH for the onset of aggregation is
qualitatively seen to be about 1 pH unit above pI for AT, in contrast to BSA for which pIpH = 0.5. Since protein concentrations are not the same, the difference in absolute values
of τ is handled by comparing the turbidimetric rates of aggregation (dτ/dt)pH. This is
calculated as (dτ/dpH) (dpH/dt), where (dτ/dpH) is obtained from Figure 1, and dpH/dt is
automatically recorded at every pH. In the resultant plot (inset of Figure 1), (dτ/dt) pH = 0
would correspond to a maximum. This indicates equal turbidimetric rates of aggregation
and disaggregation.218,219 The maximum rate of aggregation (d /dt)

pH

max

is seen at pH 6

and 5.5 for AT and BSA, respectively. For BSA, the native state is preserved over a wide
range of pH encompassing the experimental conditions here. 220-222 For AT, there are
additional suggestions of partial unfolding, 223 but not at pH~6 as used here. Those studies
refer to the dynamics of loop expulsion, presumably at a time scale that is not relevant to
our measurements of relatively slow aggregation.
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Figure 7.1: Automated turbidimetric titrations of 0.25 g/L AT (red) and 1 g/L BSA
(black) in 10 mM NaCl with the addition of 0.1 N HCl. Inset: Aggregation rate
(dτ/dt) vs pH obtained from Figure 1 for AT (red) and BSA (black).
7.4.1.2 Time dependence of AT and BSA aggregation can reveal aggregation
mechanisms
Figure 7.2 shows time dependent turbidities for AT and BSA under concentration,
ionic strength and pH conditions in the vicinity (d /dt)

pH

max

in Figure 7.1. Since cAT /

cBSA = 0.25, we focus on mechanistic differences, which are independent of protein
concentration. In Figure 7.2, the turbidity reaches a limiting value for AT and BSA at
similar times, with a larger limiting value for the former. The turbidity of AT increases
rapidly for t < 1.5 min ( Figure 7.2 , inset (a) ), while the curve for BSA exhibits only a
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small decrease in curvature at t = 25 min. Figure 7.2 inset (b) compares the aggregation
kinetics of AT and BSA using first-order plots obtained from the data in Figure 7.2. The
analysis of turbidity data in this way can be described as: 224,225
(1

e

kt

)

Eq. 7.4

where τ∞ is the limiting turbidity value at t = ∞ and k is the apparent rate constant.

Figure 7.2: Turbidimetric measurements in 10 mM NaCl for the time dependent
aggregation of 0.25 g/L AT at pH 6.1 (red) and 1 g/L BSA at pH 5.4 (black). Samples
were prepared at high pH (~ 8.5) and then brought to the desired pH within 3 min.
using 0.1 N HCl. Inset (a): Expanded time scale for the first 16 min. Inset (b): First
order fit for the time vs τ (100-%T) in for AT (red) and BSA (black) in the first 7
min.

The first order appearance of the aggregation kinetics may indicate the
mechanisms of aggregation for both proteins (vide infra). The evolution of aggregates
was also probed with DLS (Figure 7.3) in the absence and presence of Hp (the latter will
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be explained below). Contrary to turbidimetry, DLS cannot capture the first 2 min. due to
the time lag between the sample pH adjustment and measurement, but provides a better
molecular view, as seen in Figure 7.3 (a), in which cAT = cBSA = 1 g/L. The experimental
lag time, notwithstanding the rapid increase in turbidity for AT can be related to the
increase in cluster size, from < 100 nm to 300 nm during the first 15 min. Two
differences appear in Figure 7.3 (b) for BSA: the fast mode broadens as opposed to losing
intensity; and the slow mode size increases by only a factor of 2.5, from 25 nm to 65 nm.
The larger apparent initial rate from turbidity for AT appears to be due to rapid increase
in aggregate size (Figure 7.3(a)) at the end of which the fast mode (monomer) no longer
dominates the scattering intensity (data not shown).

20

20

(a)

(b)

AT ( 4 min )

BSA ( 3 min )
BSA ( 8 min )

AT ( 10 min )
AT ( 15 min )

16

BSA ( 15 min )

16

BSA - Hp ( 15 min )

AT - Hp ( 15 min )

12

Intensity (%)

Intensity (%)

12

8

8

4

4

0

0
1

10

100

R

h

1

1000

(nm)

10

100

R

h

1000

(nm)

Figure 7.3: Time dependence of particle sizes by DLS in 10 mM NaCl in the absence
and presence of Hp: (a) 1 g/L AT and 1 g/L AT with 0.1 g/L Hp (●) at pH 6.2 (b) 1
g/L BSA and 1 g/L BSA with 0.1 g/l Hp (●) at 5.4
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7.4.2 Effect of heparin on protein aggregation
7.4.2.1 Heparin suppresses aggregation of both proteins
Figure 7.4 shows inhibition of AT and BSA aggregation in the presence of Hp at
various Hp:protein ( r ) ratios. The inhibition of aggregation by Hp can be observed only
in the “pH window” bounded by formation of the heparin-protein complexes. At r = 0.1,
the stoichiometry best suited for comparison of BSA and AT, the suppression of the
aggregation is more pronounced for BSA. This is confirmed by DLS results (Figure 7.3),
in which data in the absence of Hp are combined with results in the presence of Hp
approximately 15 min. after pH adjustment (this time lag leads to a small increase in R h
for the slow mode for AT alone, and to an increase in fast mode R h for BSA alone). Here,
we see that the fast mode intensity of the free monomer (or in the case of BSA,
monomer-dimer) never exceeds 50 % for AT, but the fast mode is always the dominant
scatterer for BSA. A separate but related effect is the concentration of monomer or
monomer/dimer in the presence of Hp, obviously dependent on both the Hp-protein
binding affinity, and the Hp:protein ratio r. At r = 0.1, the doubling of the apparent size
corresponding to the fast mode for AT can only be explained by the conversion of AT
monomer to its complex with Hp. In contrast, the fast mode for BSA at r = 0.1
consistently exhibits an apparent size equal to that of the BSA dimer, regardless of time;
BSA-Hp complexes and possibly BSA dimers coexist at that condition.
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Figure 7.4: Inhibition of 0.25 g/L AT and 1 g/L BSA aggregation by heparin at 10
mM NaCl. Heparin to AT weight ratio is (r) is 0.1 and 0.4 and heparin to BSA
weight ratio (r) is 0.1 and 1.
7.4.2.2 AT-Hp binding less sensitive to salt
In order to evaluate the AT-BSA binding strength, we investigated the effect of
salt concentration on the onset of Hp-protein complex formation (Figure 7.5). This event,
pHc experimentally defined by a transition from a region of zero slope, reflects a
reversible, equilibrium phenomenon as opposed to the purely or partially kinetic behavior
described in all earlier Figures. This critical pH qualitatively represents the condition at
which the energy of complex formation just exceeds thermal energy, kT. When pHc
appears on the “wrong side of pI” (here when global protein charge is negative), (pHc –
pI) ≡ pH becomes a qualitative measure of the ability of binding to overcome this global
repulsion. Although AT and BSA have similar pI values (4.9 and 5.0), pH is larger for
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AT at all ionic strengths. Addition of salt lowers

for both AT and BSA, but the effect is

more pronounced for BSA.
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Figure 7.5: Turbidimetric titrations of AT (red), BSA (black) (0.25 g/L) and Hp
(0.025 g/L) at 10, 20, 50 mM NaCl, using 0.1 N HCl. Red and black broken lines
were used to indicate the pHc values for AT and BSA, respectively.
7.4.2.3 Hp cannot reverse AT aggregation, but can partially reverse BSA
aggregation
The inhibition of AT and BSA aggregation in the presence of Hp is a result of
soluble complex formation between protein and Hp. Hp may also interact with the larger
aggregates dissolving them into small intra-polymer complexes209,210 and in some cases
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larger inter-polymer soluble species. Figure 7.6 shows the results for AT and BSA upon
addition of Hp to a protein:Hp ratio r = 1 (w:w). The addition of Hp partially redissolves BSA aggregates (at pH 5.3) but does not reverse the aggregation of AT (at pH ~
6.1).
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Figure 7.6: Reversal of aggregation in 10 mM NaCl (a) 0.1 g/L AT and (b) 1 g/L
BSA by the addition of Hp (r = 1). Both protein solutions were prepared at pH 8.5
and pH was adjusted to 6.1 for AT and 5.3 for BSA within 3 min. using 0.1 N HCl.
Solutions were kept for 20 min. at room temperature prior to Hp addition.

7.5 Discussion
7.5.1 AT and BSA aggregation mechanisms are different
The result for AT in the Figure 7.2, inset (b), which shows the first order fit of
turbidity vs time, is in agreement with nucleation (rapid initial consumption of monomer
to form well-defined clusters) and growth (addition of monomer to these clusters), the
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first step difficult to observe for BSA. The initial AT cluster size could not be identified
because of the time lag for DLS which can only identify after 4 min. a 100 nm species for
AT (Figure 7.3 (a)), and a 25 nm species for BSA (Figure 7.3 (b)). In the first 15 min.,
the rate of depletion of the AT monomer is slightly faster than that of monomer/dimer
(BSA). There are two possible routes for the increase in turbidity over long times:
clusters either grow by association (“cluster - cluster”), or by adding monomer/dimer
(“growth”).224 The first-order appearance of the curves in Figure 7.2, inset (b) for both
proteins suggests that aggregates grow by the latter route. The transition from fast to slow
steps, seen after 2 min. for the aggregation of AT, resembles that of BLG at pH near pI
and in low salt. This protein also exhibits diffusion limited particle-cluster aggregation as
a second step.219
A notable difference between AT and BSA aggregation is seen in the evolution of
the fast mode in Figure 7.3 (b) for BSA, which in contrast to AT, broadens and shifts to
larger Rh with time. While Rh confirms to the AT monomer radius (4 nm) at all times, Rh
increases from 5 to 8 nm for BSA in the interval 3-14 min., accompanied by peak
broadening. We interpret these results as depletion of BSA monomer from the monomerdimer pool, with the concentration of monomer then determining the rate of cluster
growth, as opposed to cluster-cluster association. For AT, all un-aggregated protein is
present as the 4 nm monomer, and cluster growth is more rapid.
The absence of cluster-cluster association for both proteins can be explained by
their net charge at pH-pI > 0. However, the interaction of negatively charged AT
monomer with negatively charged clusters is ameliorated by the charge anisotropy of the
AT monomer as depicted in Figure 7.7. This same charge anisotropy also enhances
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monomer-monomer association kinetics and thus the rate of nucleation; this accounts for
the nucleation step probably present for both proteins, but more readily detected for AT.
Therefore, the greater charge anisotropy (see Figure 7.9) enhances the rate of
nucleation.218 The role of charge anisotropy of the BSA monomer is further complicated
by its equilibrium with the dimer, as evidenced by the wide range of R h values seen for its
fast mode in Figure 7.3 (b). The increase from 5 to 7.5 nm during the first 10 min. of
aggregation can be best explained as the depletion of monomer through its preferential
aggregation. In that sense, dissociation of dimer exerts some control over the rate of
aggregation.

Figure 7.7: Models for the aggregation pathways of AT and BSA.
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7.5.2 Inhibition of aggregation is a result of competition between Hp binding and
self-aggregation
The magnitude of heparin inhibition is qualitatively assessed by comparison of
turbidimetric titrations with and without Hp for the two proteins. As shown in Figure 4,
the inhibition effect depends on the heparin concentration (or bulk weight ratio r).
Together with the protein-Hp binding affinity, this stoichiometry controls the fraction of
protein that forms complex, and thereby controls the aggregation rate by modulating the
free protein concentration. The assumption is that heparin-protein complexes have no
direct influence on aggregation kinetics. At equal r = 0.1, the concentration of total
protein is 4-fold smaller for AT than for BSA, but the intrinsically rapid aggregation of
free AT results in larger turbidity.
Evidence of the depletion of protein monomer upon addition of Hp should emerge
from DLS. In Figure 7.3 (a), AT monomer (R h = 4 nm) is well resolved from complex at
Rh = 8.5 nm, and is seen to be fully converted to a mixture of small and large complexes
in the presence of Hp. BSA aggregate clusters vanish in the presence of Hp (Figure 7.3
(b)) but the ca. 8 nm complexes cannot be well resolved from BSA monomer/dimer. BSA
monomer/dimer persists in the presence of Hp because of its relatively low Hp affinity;
but BSA aggregates fail to form. The effect of Hp on BSA aggregation relative to its
weaker effect on AT aggregation, may be related to the differences in aggregate or
aggregation mechanism, most notably the presence of an obvious nucleation step for AT.
The amount of Hp required for suppression is r = 0.1 for BSA and r = 0.4 for AT. The
larger requirement for AT suppression despite its stronger binding is a reflection of the
strong tendency of its monomer to aggregate even at lower concentration. The second
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effect of r is the shift of pHφ to lower pH.209 This phase separation occurs when
complexes achieve charge neutrality. When the ratio of Hp to protein is large, each Hp
binds few proteins, and the positive charge per protein needed to overcome Hp charge is
large, which corresponds to low pHφ.

7.5.3 Stronger binding of Hp to AT, notably at high salt, manifested as high values
of pHc
We proceed to interpret the results of Figure 5 in terms of binding constants for
Hp-BSA and Hp-AT measured elsewhere. The ionic strength dependence of pHc shown
in Figure 7.8 (a) provides a qualitative comparison of Hp affinity for AT vs BSA: the
expanded domain of complexation seen for AT indicates its stronger heparin binding.
Corresponding measurements by FACCE28,51 verifies this more quantitatively, and both
measurements show that the difference in Hp affinity between AT and BSA strongly
increases with added salt (Figure 7.8 (b)). Interestingly, the frequently noted linear loglog dependence of Hp-protein binding17 is seen to apply only at I > 10 mM for BSA and
25 mM for AT.
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Figure 7.8: (a) Ionic strength dependence of pH c obtained from turbidimetry (from
Figure 7.5). The dashed lines are drawn to guide the eye. (b) Ionic strength
dependence of the binding constant obtained by FACCE. The data for BSA and AT
from ref. 51 and ref. 28.

The differences between BSA and AT in Figure 7.8 can now be explained by the
charge distributions of the two proteins as represented by DelPhi images (Figure 7.9).
The maximum in the plot for AT has been interpreted in terms of combined attractive and
repulsive forces,28 which should be more important for AT because of its charge
anisotropy. The more pronounced positive domain for AT leads to the formation of an
AT-Hp complex that is more salt resistant than the BSA-Hp complex. This is also
reflected in the persistence at high salt of the positive (Hp-binding) electrostatic domain
of AT, and the virtual disappearance of this domain for BSA at 100 mM salt, entirely
consistent with the drop in log K at log I = -1 for BSA in Figure 7.8 (b).
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Figure 7.9: Ionic strength dependence of the electrostatic potential contours at - 0.5
kT/e (red) and 0.5 kT/e (blue) for AT and BSA at pH 6.0.
7.5.4 Aggregate fractal dimensions larger for AT than for BSA
The greater charge anisotropy for AT vs. BSA is not only consistent with its
stronger Hp binding, but may also explain the inability of Hp to reverse AT aggregation
as shown in Figure 7.6. This apparently contradictory relation, the resistance to Hpinduced dissolution is greater for the protein with higher Hp affinity, can be understood
in terms of aggregate formation and density. Recent Monte Carlo simulations have
contrasted the aggregation behavior of uniformly and non-uniformly charged colloids, in
which the latter interact more strongly and form larger clusters. 226 While both proteins
here exhibit charge anisotropy, AT more nearly resembles the extreme case of nonuniform charge with correspondingly strong short-range attraction. This is expected to
lead to a densely packed aggregate, resistant to dissolution. The binding of Hp as an
inhibitor of aggregation can be considered energetically in terms of the equilibrium
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between complex and free protein, reducing its concentration and thus lowering the rate
of aggregation. The stabilization of the former might be considered to arise from multiple
interactions of the flexible Hp chain with the protein. Similar considerations have been
referred to as “multivalency”, but this does not reflect the role of polyelectrolyte chain
dynamics. Aggregate dissolution follows a different path involving Hp diffusion onto and
into aggregates, and a variety of subsequent kinetically controlled steps which cannot be
readily identified by the current methods. The structure of the aggregate may play a role
at least as significant as the intrinsic protein-Hp molecular affinity discussed above.
To support this latter hypothesis, fractal dimensions of AT aggregates were
determined by static light scattering (Figure 7.10) and compared to published results for
BSA. The difference between Df (AT) = 2.3 ± 0.1 (Figure 7.10 (c)) and 1.7 (BSA) 227
supports the argument that the greater density for AT aggregates makes them impervious
to dissolution by Hp. However, when Hp is initially present with AT at pH 8 and r = 0.1
(prior to adjustment to pH 6.1) similar SLS measurements lead to Df (AT-Hp) = 0.8 ±
0.1, consistent with a highly extended rod-like chain. Since AT is net-negative at this pH,
both steric and electrostatic effects lead to intra-polymer repulsion in the Hp-AT complex
and consequent chain stiffness. To our knowledge, this is the first reported measurement
of the fractal dimension of an Hp-protein complex. Nominally, the values of R g / Rh are
0.8 and 0.9 for aggregated AT and AT-Hp complex, respectively from the Guinier plot
shown in Figure 7.10 (b). The former, very close to the limiting value for spheres, is
consistent with the large value of Df, but the latter is not consistent with the extended
conformation deduced from Df = 0.8. These ratios must be considered in the light of the
averaging of signals from large and small scatterers for both systems, unavoidable for
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SANS and arbitrary for DLS. These averages tend to be weighted more toward the
smaller species in Malvern due to backscattering. More accurate results will require angle
dependence of diffusion coefficients complementary to Figure 7.10 (a).
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Figure 7.10: SLS of 1 g/L AT and 1 g/L AT and 0.1 g/L Hp (r = 0.1) in 10 mM NaCl,
pH = 6.2 (a) Scattering intensity (I) as a function of scattering vector (q), (b) Guinier
plot to determine Rg in the low-q region and (c) High-q region to determine fractal
dimensions of AT aggregates and AT-Hp complex.

126

-3.50

7.6 Conclusions
Heparin (Hp) inhibits and reverses aggregation more completely for BSA than for
antithrombin (AT). Since heparin binds more strongly to AT, this difference is not due to
the conversion of protein monomer/dimer to non-aggregating complex, which would be
greater for Hp. The reduced effects of heparin for AT occur because the relatively low
concentration of uncomplexed AT monomer aggregates far more extensively than the
more abundant BSA monomer/dimer. The values of pH at which complexes are first
observed at different ionic strengths, relative to pI a measure of the ability of binding to
overcome repulsion between heparin and global protein charge -- is in good qualitative
agreement with measurements of binding constants by FACCE. These two measures of
protein-heparin affinity are shown to be consistent with protein charge anisotropy as
revealed by electrostatic modeling. In contrast to inhibition, the reversal of protein
aggregation by heparin is also influenced by aggregate structure: the low fractal
dimensions of BSA aggregates make them more susceptible to dissolution mediated by
heparin binding.
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CHAPTER 8
CONCLUSIONS AND FUTURE STUDIES
We have investigated the effects of heparin charge density and chain length in
protein binding taking into account both polyelectrolyte properties of heparin and
electrostatic interactions between heparin and protein. Charge complementarities between
the protein surface and heparin were found to play significant roles in the protein
recognition process. In addition, conservation of heparin chain dynamics in the bound
state lead us to consider a more nuanced “specificity” and “selectivity” of heparin in
protein binding, as opposed to the classical “lock” and “key” type interaction, in which
heparin is thought to have specific conformation in order to bind to a well defined epitope
on the protein surface.
Our studies showed that heparin is subjected to counterion condensation, and the
degree of condensation exhibits an inverse relation with chain length, which is due to the
diminished condensation at the chain ends. The remarkable success of the simplified
model (as presented in Figure 2.6) to establish effective charge calculations for heparin
oligomers, in which each sulfate group is treated as the same, could indicate the
significance of overall sulfation, rather than precise sulfate locations to define heparin
chain properties. Contrary to Hp, HS structure is comprised of well-defined low (NA)
and high sulfation (NS) domains; therefore, the junctions could lead to preservation of the
high effective charge density of NS domains by inhibiting counterion condensation. This
hypothesis could be tested by measuring the elecrophoretic mobility distributions of HS
oligomers and compare them with the heparin oligomer mobilities. The preservation of
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the HS high effective charge density could be significant in mediating growth factor
binding on the cell surface.
The contribution of counterion condensation in heparin/HS-protein interactions,
i.e. the significance of effective charges as opposed to structural charges in protein
binding, is not well understood. It has been proposed that heparin-protein binding is
analogous to DNA-oligolysine interactions, in the sense of being driven by the entropy of
expelled counterions. In this case, an increase in the effective charge of the proteinbinding domain on HS could amplify the binding constant in comparison to heparin.
This hypothesis could be tested by measuring the apparent association constants between
FGF (or AT) –HS and Hp oligomers using frontal analysis capillary electrophoresis
(FACCE). If the effective charges are the major determinants for protein binding, we will
observe higher association constants with HS compared to Hp.
Highly sulfated heparin oligomer chains were able to induce the formation of
multimeric complexes of FGF. This observation could demonstrate that these highly
sulfated chains might have the optimal binding sites, i.e. properly arranged charged
segments, compared to the lower sulfated chains. The sulfation pattern could be
determined by isolating bound Hp/HS oligomers using size exclusion chromatography or
capillary electrophoresis, and the isolated Hp/HS fractions could be further subfractionated using strong anion exchange chromatography. Then, these sub-fractions
could be sequenced using ESI MS fragmentation methods such as collision-induced
dissociation (CID) or electron detachment dissociation (EDD). Complementary to ESI
MS, Monte Carlo simulations can be applied in FGF and heparin oligomer interactions in
order to elucidate the structural selectivity of Hp/HS. Monte Carlo simulations could
129

enable identifying the Hp/HS configurational flexibility at the protein-bound state, and
also calculate the binding energies for the high and low affinity Hp/HS oligomers which
were identified from the prior ESI MS studies. These concerted efforts of elucidating
affinity, structural charge distribution, and the chain dynamics of HS/Hp could provide a
better understanding of the selectivity and the plasticity of protein-HS/Hp interactions.
The convergence of ESI MS and simulation studies in order to determine HS/Hp binding
motif could build confidence to employ longer HS/Hp oligosaccharides in growth factor
interactions. The complementarities between protein surface charge and detected HS/Hp
binding motifs could be used to predict the relative affinities of various protein-Hp/HS
pairs, which could explain how Hp/HS provide binding sites for a multitude of proteins.
The incorporation of well-defined heparin oligomers into biomedical scaffolds is
a new approach in tissue engineering. In our model system, heparin decamer (dp10)
could bind both tetralysine (K4) and a growth factor (FGF1). Tetralysine is bound in
regions rich in condensed counterions, as opposed to chain ends, and the binding of a
single tetralysine, which still leaves “space” for FGF to bind, is significantly weaker than
the binding of FGF. An alternative approach, more relevant to tissue engineering
applications, would be an examination of longer Hp chains where the ratio of condensed
counterions to structural charges would be larger, so that binding of oligopeptide and
FGF on the heparin oligomer chain could be more competitive. Cationic biopolymer
chitosan is an alternative for oligopeptide as a scaffold material because chitosan has a
high degree of biocompatibility andbiodegradability, its chemical structure can be easily
modified, and it form complexes with heparin. Heparin-chitosan complexes can be used
as a platform for growth factor delivery, and using oligoheparins and oligochitosans, as
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opposed to native heparin and high molecular weight chitosan, could provide a better
control for growth factor capture and release due to the reduced heterogeneity. The
binding of oligoheparin to low-charge density chitosan could be weaker than growth
factor-heparin oligomer binding; however the extent to which oligochitosan interferes
with growth factor binding should be elucidated. Therefore, the ternary complex
formation between heparin oligomers, oligochitosans and growth factors can be
investigated using ESI MS at varying ionic strength and pH values.
Monte Carlo simulations could also be used to propose interaction mechanisms
for FGF-Hp and AT-FXa - Hp interactions taking into account our ESI MS results.
Monte Carlo simulations showed that a small portion of the Hp mimetic interacted with
FGF at any time. This result could be used to assess the mechanism of three FGF
molecules binding to Hp decamer chain, in which three FGF molecules may be bridged
by heparin oligomer with transient interactions. This observation may raise a possibility
for their catalytical roles in growth factor binding, which has also suggested in AT
interactions with coagulation proteases. Our ESI MS studies indicated that short Hp
chains (dp ≤ 10) promote binary AT·FXa complexes. Shorter Hp chains may transiently
bridge the positive domains of AT and FXa, but that the most favorable orientation of AT
and FXa may no longer need that bridge. Thus, Monte Carlo simulation could be
employed in AT, FXa, and short heparin chain (dp ≤ 10) binding to probe the dynamics
of the polymer and its ability to stabilize AT-FXa complex. This could provide a better
understanding of how short heparin chains catalyze the formation of binary complex and
at what stage heparin oligomer dissociates from the complex.
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The resultant AT-FXa complex has been suggested as covalent, and this covalent
nature of can be further investigated either with MS/MS fragmentation methods or by
inducing dissociation in solution via acid-induced denaturation. In addition, ESI MS
spectrum of AT and FXa in the presence of native heparin showed evidence of higher
order complexes; however the complex peaks were not resolved due to extensive
heterogeneity. This experiment can be repeated using FTICR MS, and limited charge
reduction method can be applied to isolate the complex peaks, and then determine the
exact stoichiometry of the AT-FXa complexes.
The complex formation between native heparin and AT was studied using limited
charge reduction method on FTICR MS, and 1:1, 2:1 and 1:2 (AT:Hp) complexes were
detected. This could show that there are multiple Hp binding sites on one AT, as well as
multiple AT binding sites on one Hp. The formation higher order complexes on the
heparin chain can be studied by varying the solution mixing ratio between AT and Hp.
Complementary to mass spectrometry, small-angle scattering techniques, such as smallangle neutron scattering (SANS) or small angle X-ray scattering (SAXS) can be
employed to determine size, shape and structure of the complexes. By this way, the
proximity of the bound proteins on the Hp/HS chains can be detected.
AT aggregation has been studied in the absence and in the presence of heparin
and the morphology of the AT aggregates and AT-Hp complexes have shown different
structural features, as revealed by the measured fractal dimensions in static light
scattering (SLS). Small-angle scattering techniques, which accesses wider range of qvalues than SLS, could be used to probe the structural arrangements, correlation length
and the dynamics of AT aggregates and higher order AT-Hp complexes.
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